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Proteomic techniques evaluate levels and post-translational modifications 
of a large number of proteins simultaneously. Currently, proteomics has 
been used for studying human diseases in a wide variety of biomedical 
areas including cardiovascular diseases, cancer, neurological disorders, 
and respiratory diseases. The proteomic approach allows us to search for 
new bio-markers and explore the pathogenesis of allergic airway 
inflammation based on the analysis of protein expression differences 
between healthy state and diseased state.  
The purpose of this study was firstly to analyse and quantify the 
alterations in global protein expression in bronchoalveolar lavage (BAL) 
fluid from mice with acute allergic airway inflammation compared with 
normal mice by employing a proteomic technology. A typical 2-dimensional 
map of BAL fluid of mouse was constructed. Secondly, the protein profiles 
from both BAL fluid and lung tissue from mice with chronic allergic airway 
inflammation were compared with the samples from normal mice. A typical 
2-dimensional map of lung tissue of mouse was also constructed. Finally, 
we investigated pharmacoproteomics of a glucocorticoid drug, 
dexamethasone, the most effective class of drug for treating asthma, in an 
acute allergic mouse asthma model. 
To achieve these objectives, representative animal models are required. 
No single animal asthma model can simulate all features of human asthma. 
 viii
Therefore, we established two types of asthma model, the acute and the 
chronic, to demonstrate different stages of asthma conditions in human. 
The acute asthma model focuses on early asthmatic responses and 
airway acute inflammation with mild structural changes, while the chronic 
asthma model illustrates more features of airway structural alterations but 
the acute airway inflammation is attenuated. 
We have identified many classes of proteins which were for the first time 
shown to be related to the pathophysiology of asthma. Our findings shed 
new light on the exploration of new mechanisms of the development of 
asthma. The identified proteins may be considered as potential biomarkers 
for monitoring the progression of asthma or potential therapeutic targets 
for novel drug development. Moreover, the pharmacoproteomics study 
further broadens our understanding of the spectrum of gene target 
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1.1. Proteomics  
 
1.1.1. Proteomics and genomics  
The word ‘proteome’ was first coined in 1994 to describe all proteins content 
present in a cell, tissue, or body fluid at a given time (Wilkins et al., 1996). The 
study of the proteome, called proteomics, was proposed in 1995 and was 
defined as the identification and characterization of the entire protein 
complement, or proteome, of a biological system (Wasinger et al., 1995). The 
definition of proteomics has changed greatly over time. Originally, it was 
coined to describe the large-scale, high-throughput separation and 
subsequent identification of proteins resolved by 2-dimensional 
electrophoresis (2-DE). Currently, proteomics denotes nearly any type of 
technology focusing upon proteins analysis, ranging from a single protein to 
thousands in one experiment. Proteomics thus has replaced the phrase 
‘protein science’ (Baak et al., 2005). 
  The growth of proteomics is a direct result of rapid advances made in 
genome study. The first complete genome of an organism, Hemophilus 
influenzae, was sequenced in 1995, 42 years after the landmark description of 
the DNA double helix structure in 1953 (Guttmacher and Collins, 2003). Since 
then, the DNA information has been acceleratively accumulated. To date, 
about 360 complete genomes have been published which include around 300 
bacterial genomes and over 40 eukaryotic genomes. Over 1500 new genome 
sequencing projects are ongoing covering all kinds of organisms 
(http://www.genomesonline.org/). Among these progresses, the completion of 
Human Genome Project (officially announced on April 14, 2003) was 
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undoubtedly most exciting event in the genomic world which introduced the 
‘post-genomic era’ (Guttmacher and Collins, 2003; Mocellin et al., 2004). 
From genome to proteome: Human genome has 2.9 gigabases (Gb) 
(International Human Genome Sequencing Consortium, 2001) as compared 
with rat (2.75 Gb) (Rat Genome Sequencing Project Consortium, 2004), 
mouse (2.6 Gb) (Mouse Genome Sequencing Project Consortium, 2002), 
chicken (1 Gb) (International Chicken Genome Sequencing Consortium, 
2004), and fruit fly (0.12 Gb) (Adams et al., 2000). Notwithstanding, these 
genomes can encode similar number of genes (20,000-25,000 genes), in 
contrast to 13,000 genes encoded in fruit fly (Adams et al., 2000). This 
indicates that the absolute number of genes may not be enough to explain the 
phenotype complexity.  
The information encoded by genomes does not describe the dynamics of 
the life processes occurring in cells and organisms. Healthy as well as 
disease status are governed by complex processes, which start from the 
activation of a limited number of genes located in the genome either on the 
same chromosome or in different chromosome segments. Gene activation, 
translation, transcription as well as posttranslational modifications give rise to 
a multitude of mature proteins and peptides with different structures, which 
are not directly deducible from genome sequences (Crameri, 2005). Although 
proteins and peptides are products of gene expression, there are much more 
different forms of functional proteins and peptides than genes encoding them. 
As a consequence of the tightly regulated synthesis, posttranslational 
modifications and degradation, every cell, tissue and organ of an organism 
contains a complex pool of proteins, protein fragments and peptides 
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adequately modified to fulfill their biological functions. One gene can be 
transformed to a whole family of gene products via alternative splicing and 
other mechanisms. Furthermore, the correlation between mRNA and protein 
concentrations has been demonstrated to be insufficient to predict protein 
expression levels from quantitative mRNA data (Gygi et al., 1999b), partially 
because the formation of proteins is regulated by multiple steps.  
Therefore, the study of the genome or even mRNA levels (the transcriptome) 
will reveal only a small spectrum of the responses to a particular stimulus. 
mRNA levels tell us nothing about the regulatory status of the corresponding 
proteins, whose activities and functions are subject to many endogenous 
posttranslational modifications and other modifications by environmental 
agents. Moreover, proteins, but not genes, are responsible for the phenotypes 
of cells. Only through the study of proteins can protein modification be 
characterized and the targets of drugs be identified.  
 
1.1.2. Protein sample preparation 
A typical proteomics experiment (such as protein expression profiling) can be 
broken down into the following steps: (i) the separation and isolation of 
proteins from a cell line, tissue, or organism; (ii) the acquisition of protein 
structural information for the purposes of protein identification and 
characterization; and (iii) database utilization (Graves and Haystead, 2002).  
In a proteomics study, we normally start with a biological sample: a piece of 
tissue or a flask of cultured cells. The sample then is usually pulverized, 
homogenized, sonicated, or otherwise disrupted to yield a soup that contains 
subcellular components and debris in an aqueous buffer or suspension. The 
 5
proteins are extracted from the mixture with the aid of detergents (e.g. 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)) which help 
to solubilize membrane proteins and aid their separation from lipids, 
reductants (e.g. dithiothreitol (DTT)) which reduce disulfide bonds or prevent 
protein oxidation, denaturing agents (e.g. urea) which disrupt protein-protein 
interactions, secondary and tertiary structures by altering solution ionic 
strength and pH, and enzymes (e.g. DNAse) which digest contaminating 
nucleic acids, carbohydrates, and lipids (Rabilloud, 1996).  
  Because many components of biological samples can interfere with 
analysis, it is imperative to remove them before study. Insoluble substances 
can be removed by centrifugation. For 2D-PAGE and mass spectrometry, it is 
necessary to remove salts before analysis. This can be achieved by dialysis, 
size-exclusion filtering, protein precipitation, or reverse-phase (RP) 
chromatography (Issaq et al., 2002a). Frequently, abundant proteins such as 
albumin or immunoglobulins need to be removed first (Wu et al., 2005). 
Complex samples need to be fractionated before analysis to obtain simpler 
subfractions and to decrease the dynamic range of components, if possible. 
For example, the dynamic range of concentrations in a plasma sample 
exceeds 10 orders of magnitude (Hirsch et al., 2004), whereas a current one-
dimensional chromatography-mass spectrometry approach can only detect 
proteins in a dynamic range of approximately 4 orders of magnitude (Hirsch et 
al., 2004). Affinity purification is a powerful approach to reduce the complexity 
of a sample by specifically isolating individual proteins or “protein complexes” 
(Bauer and Kuster, 2003). These preparation steps are often more time 
consuming than the subsequent analysis steps and influence the sensitivity 
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and discriminative power of mass spectrometry-based protein identification 
(Issaq et al, 2002a).  
Laser capture microdissection (LCM): The advent of LCM, first 
introduced by Emmert-Buck et al. (Bonner et al., 1997), has enhanced our 
ability to collect specific subpopulations of cells of interest from frozen or fixed 
tissues under direct microscopic visualization (Figure 1). Two-dimensional 
electrophoresis can greatly benefit by applying LCM because LCM method 
significantly decreases the heterogeneity of the sample, especially in the field 
of cancer research (Lawrie and Curran, 2005).   
 
1.1.3. Protein separation  
The idea behind separating protein mixtures is to take advantage of their 
diversity in physical properties, especially isoelectric point and molecular 
weight (O’farrel, 1975). The mixture may be separated into many fractions 
which then are taken for proteolytic digestion followed either by further 
separation of the peptide fragments or direct MS analysis of the peptides. The 
methods being used for protein separation are mainly based on either 
electrophoretic or chromatographic techniques, or a combination of these two 
techniques (Issaq et al., 2005).   
 
1.1.3.1. Two-dimensional electrophoresis (2-DE) 
The current standard method for the separation of protein complex is still 2-
dimensional poly-acrylamide gel electrophoresis (2D-PAGE), a method 
developed about 30 years ago (O’farrel, 1975). 2D-PAGE is actually a 




















Figure 1. Schematic summarizing the steps in the LCM. LCM uses a laser 
beam and transfer film to lift the desired cells out of the tissue sample, 
separating the unwanted cells and tissue from the sample for analysis. The 
transparent transfer film is placed on the surface of the tissue sample, and by 
using a microscope the researcher selects a group of cells. The laser diode 
produces a pulsed laser beam that is directed onto the transfer film directly 
above the desired cluster of cells. The laser melts the transfer film, fusing the 
cells with the film.  When the film is removed from the tissue sample the 









proteins are resolved on the basis of isoelectric point (pI) by isoelectric 
focusing (IEF). In the second dimension, focused proteins then are further 
separated by SDS-PAGE according to their molecular weight.  
  A number of improvements have been made in 2-DE over the years. 
Introduction of denaturing conditions for protein solubilization by adding urea 
and detergent increased solubility and resolution significantly and is the basis 
of modern 2-DE (O’farrel, 1975).  
Carrier ampholyte (CA) had been used to generate pH gradient required for 
IEF for a few years, however, it was difficult to obtain reproducible results 
using CA-generated pH gradients for reasons such as pH gradient instability 
over time, cathodic drift, and batch-to-batch variability of synthetic CAs (Gorg 
et al., 2004). These shortcomings have been largely overcome by the 
development of immobilized pH gradient (IPG) (Bjellqvist et al., 1982). The pH 
gradients are prepared by co-polymerizing acrylamide monomers with bi-
functional Immobiline reagents, a series of ten chemically well defined 
acrylamide derivatives containing carboxylic and tertiary amino groups. These 
form a series of buffers with different pK values between pK 1 and 13. 
Because the buffering groups are fixed, the gradient cannot drift and is not 
influenced by the sample composition. The appearance of IPG is one of the 
biggest improvements which greatly increases the resolution by the ability to 
generate narrow pH gradients (Δ pH up to 0.001) (Gorg et al., 1988), and 
loading capacity (Bjellqvist et al., 1993). Consequently, pre-manufactured IPG 
strips and dedicated instruments are available as commercial products which 
make 2-DE a reproducible and reliable method. Isoelectric focusing (IEF) with 
IPGs is the current method of choice for the first dimension of 2-DE for most 
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proteomic applications.  
More recently, narrow range IPG strips have been developed for the first 
dimension of 2-DE (Hoving et al., 2000). The strips are typically of 1-3 pH 
units wide with overlapping pH range, e.g. pH 4.5-5.5, 5-6, and 6.2-8.2. A 
narrow pH gradient strip combines two advantages: it has a higher loading 
capacity and allows increased spatial resolution.   
Different staining methods have been developed for the protein detection, 
such as Coomassie Blue staining, silver staining, radioactive labeling, and 
fluorescence staining (Hirsch et al., 2004; Gorg et al., 2004). The detection 
sensitivity varies from 100 ng of proteins for Coomassie staining to 200 fg of 
proteins for radiography. Due to the shortcomings of the organic dyes, 
radiolabelling and silver staining for visualization and quantitation of proteins, 
fluorescent detection has increasingly gained popularity for proteomic analysis. 
Two major approaches for the fluorescent detection, pre-electrophoretic 
staining (Urwin and Jackson, 1993) and post-electrophoretic staining 
(Berggren et al., 2002), are currently practiced.  
To shorten the laborious procedures of 2-DE and eliminate the experimental 
variation due to inhomogeneity in poly-acrylamide gels, electrical and pH 
fields, and thermal fluctuations, a new methodology called Difference In-Gel 
Electrophoresis (DIGE) was introduced by Unlu et al. (1997). In this method, 
two fluorescent cyanine dyes (Cy3 and Cy5) are commonly used to label two 
different samples which are subsequently mixed and run on the same gel. 
These two dyes are mass- and charge- matched and they possess distinct 
excitation and emission spectra. Due to the co-migration of both samples, 
methodological variations in spot positions and densities are excluded, and, 
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consequently, image analysis is facilitated considerably. In later studies (Alban 
et al., 2003), a third dye (Cy2) was used as an internal standard to provide a 
link for inter-gel comparison and to facilitate a more robust statistical analysis 
(Figure 2). However, the instrumentation requirement restricts the popular use 
of this method. Sample loading capacity is also a concern. 
As the 2-DE experiments result in large amounts of data, efficient use of the 
2D techniques relies on powerful and user-friendly data analysis system. The 
development of software for 2-DE gel image analysis is continuously ongoing. 
The functions become more reliable, reproducible and automated from year to 
year. A number of software packages have appeared in the last decade, 
including Delta 2D (DECODON GmbH), GELLAB (Scanalytics), Melanie 
(Geneva Bioinformatics), PD Quest (Bio-Rad Laboratories), Phoretix 2D 
(Nonlinear Dynamics), Progenesis (Nonlinear Dynamics), AlphaMatch 2D 
(Alpha Innotech), Image Master 2D (Amersham Pharmacia), Investigator HT 
(Genomic Solutions), Z3 (Compugen), and Proteomeweaver (Definiens). New 
software packages or new versions of current packages are being developed 
which help us in terms of fast and automated image analysis with less manual 





























Figure 2. Workflow for DIGE system showing co-separation of three 
fluorescently labeled samples separated on a single 2-D gel. One sample is 







Proteomics is described as a high-throughput technique dealing with a large 
amount of samples. Therefore the automation of as many steps in the analytic 
process as possible is need. In addition to instrumental improvements such as 
Proteam IEF (Bia-Rad Laboratories) which allows up to 24 strips to run at the 
same time, a method called molecular scanner has been developed recently 
(Binz et al., 2004). Using this method, all proteins of a 2-DE are first 
simultaneously digested and electro-transferred onto a membrane which is 
then directly scanned by MALDI-TOF MS (matrix-assisted laser desorption 
ionization- time-of-flight mass spectrometry). After searching database using 
software, a fully annotated 2-D map is created on-line. This method provides a 
new direction for automation of proteomics.   
Although 2-DE is labor intensive and has some limitations such as limited 
dynamic range, it is still preferred for large-scale separation of complex 
protein mixtures. One of its key strengths is its ability to allow investigators to 
compare protein expression levels in cells under different environmental 
conditions or treatments. It can separate thousands of proteins in one gel. In 
fact, this technique offers the best possible resolution because it separates 
proteins according to two independent physicochemical parameters: pI and 
size. Furthermore, the gel acts as an efficient fraction collector that stores the 
proteins until pickup. So 2-DE is currently the most important technique that 
can be routinely applied for parallel quantitative expression profiling of large 





1.1.3.2. Chromatography  
2-DE based proteomic approach provides an unparalleled resolving power; 
however, it has some problems. The most important one is that its limited 
dynamic range. Resolving proteins with extreme pI, e.g. above pH 10 or 
below pH 3, is still difficult. Inability to detect low-copy proteins is always the 
drawback of 2-DE. These limitations have inspired the development of 
alternative technologies which could be either purely chromatographic or 
hybrid chromatographic/electrophoretic methods. The applicable techniques 
are mainly high performance liquid chromatography (HPLC) and capillary 
electrophoresis (CE). Different modes of HPLC (reversed-phase, ion 
exchange, size exclusion, affinity, hydrophobic interaction) and CE (capillary 
zone, isoelectric focusing, isotachophoresis, affinity) (Table 1) and a 
combination of both techniques provide numerous options for developing 
liquid phase based strategies for the separation of complex mixtures of 
proteins and peptides (Wang and Hanash, 2003; Issaq et al., 2005). The 
advantage is that chromatographic methods are automatable, sensitive, and 
reproducible.  
Table 1. List of various chromatographic methods used to separate proteins 
based on their physical or chemical property (Issaq et al., 2005).  
 
Technique Physical/chemical property 
HPLC  
Size exclusion chromatography (SEC) Stoke's radius 
Hydrophobic interaction chromatography Hydrophobicity 
Reversed-phase chromatography Hydrophobicity 
Ion-exchange chromatography (IEC) Charge 
Affinity chromatography Specific biomolecular interaction 
CE Size/charge 
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In current chromatographic approaches, in most cases, the proteins are 
digested into peptides prior to separation. The advantage is that peptides 
(especially from membrane proteins) are more soluble in a wider range of 
solvents and hence easier to separate than proteins. The disadvantage is the 
tremendous increment in the number of peptides to be resolved. 
Multidimensional separation methods are necessary to simplify such complex 
mixtures to allow for the greatest number of peptides to be successfully 
identified by subsequent MS analysis (Issaq et al., 2005). 
 
1.1.3.2.1. Two-dimensional approaches  
Chromatography was first used in 1960 by Moore and Lee to fractionate water 
soluble proteins from liver by ion exchange chromatography on a 
diethylaminoethyl (DEAE) cellulose column (Moore and Lee, 1960). Since 
then, many different chromatographic and electrophoretic methods have been 
developed for fractionating proteins and peptides. 
SEC/RPLC: Opiteck and co-workers (1997, 1998) described a 2-
dimensional HPLC system that used size-exclusion chromatography (SEC) 
followed by reversed-phase (RP)-HPLC for the isolation of over-expressed 
proteins and proteome mapping of proteins extracted from E. coli.  
IEC(SCX)/RPLC: One of the most successful approaches, though, is the 
one by Yates and co-workers (Link et al., 1999), who developed an on-line 
multidimensional protein identification technology (MudPIT) where the strong 
cation exchange (SCX) column was coupled to RP-HPLC, to separate a 
mixture comprised of a tryptic digest of 80S ribosomes isolated from yeast. In 
a later study (Washburn et al., 2001), this group identified almost 1500 
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proteins extracted from a total yeast lysate using MudPIT strategy. Similar 
procedures were used for the separation of peptides and proteins in human 
plasma filtrate (Raida et al., 1999), plasma peptides (Richter et al., 1999), 
blood ultrafiltrate (Schrader et al., 1997), and human urine (Heine et al., 1997). 
Today the combination of ion exchange liquid chromatography (IEC) (mainly 
SCX chromatography) in the first dimension and RP-HPLC in the second 
dimension, are the dominant procedures for the separation of proteome 
digests (Issaq et al., 2005). 
RPLC/CE: Jorgenson and coworkers (Lewisa et al., 1997) have developed 
an elegant on-line multicolumn RP-HPLC/capillary zone electrophoresis (CZE) 
approach in which the first dimension was RP-HPLC coupled to the second 
dimension CZE to analyze many fractions eluting from the HPLC column. 
Issaq et al. (Issaq et al., 1999) used an off-line RP-HPLC/CE system for 
separating a protein digest. The CE separation mode can be either CZE for 
separation of peptides or capillary gel electrophoresis (CGE) for the 
separation of proteins. The advantages of an on-line approach are speed and 
high throughput; however, such approaches have their limitations. There are 
stringent requirements, such as time requirement for the second dimension, 
the size limitation of the columns used, and special instrumental requirement. 
An off-line approach, although slower, and may lead to sample loss, has 
several advantages such as easy to perform and larger sample loading (Issaq 
et al., 2005). 
Affinity/RPLC: Affinity chromatography is used when a specific subset of 
complex mixture, such as glycopeptides and phosphopeptides, is concerned. 
Regnier and coworkers used lectin affinity chromatography for the 
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identification of glycoproteins in complex mixtures derived from either human 
blood serum or a cancer cell line (Geng et al., 2001). In another study from 
the same laboratory, Cu2+ immobilized metal-affinity chromatography (IMAC) 
in tandem with RPLC was applied to a yeast protein extract in which peptides 
rich in histidyl residues were selected. Concanavalin A affinity 
chromatography was used to extract glycopeptides from whole serum (Apffel 
et al., 1996). Recently, Hunt and coworkers (Ficarro et al., 2002) reported a 
separation strategy that enables characterization of phosphopeptides from 
whole cell lysates in a single experiment by coupling IMAC with RPLC-MS.  
One of major shortcomings of chromatography-based approaches is the 
lack of quantitative information (Hirsch et al., 2004). To circumvent this 
problem a method called isotope-coded affinity tags (ICAT) has been 
developed. This approach was first introduced by Gygi et al (Gygi et al., 
1999a). The isotope-coded affinity tags reagent consists of three components 
(Figure 3): a thiol-specific reactive group for alkylating Cys residues, a 
polyether linker containing either eight hydrogen atoms (light) or eight 
deuterium atoms (heavy), and a biotin group which is used to isolate ICAT-
labeled peptides during the chromatography phase. There is an 8 Da mass 
difference between the same peptides from two different samples labeled with 
either heavy ICAT or light ICAT. Thus in MS, the ratios between the intensities 
of the lower and upper mass components of these pairs of peaks provide an 
accurate measure of the relative abundance of the peptides (and hence the 
proteins). This method offers a powerful approach for identification and 
quantitation of proteins, including membrane and low-abundance proteins 





























Figure 3. The ICAT strategy for quantitating differential protein expression 
(Gygi et al., 1999a). Two protein mixtures representing two different cell states 
have been treated with the isotopically light and heavy ICAT reagents, 
respectively; and an ICAT reagent is covalently attached to each cysteinyl 
residue in every protein. The protein mixtures are combined and proteolyzed 
to peptides, and ICAT-labeled peptides are isolated utilizing the biotin tag. A 
pair of ICAT-labeled peptides is chemically identical and there is an 8 Da 
mass difference measured in a scanning mass spectrometer (four m/z units 
difference for a doubly-charged ion). The protein is identified and the relative 
quantification is determined by the ratio of the peptide pairs.  
 
CE/CE: An on-line combination of capillary isoelectric focusing (CIEF) with 
transient capillary isotachophoresis/zone electrophoresis (CITP/CZE) in an 
integrated platform was introduced (Mohan et al., 2003). Dovichi and 
coworkers reported a CE/CE system for automated protein analysis (Michels 
et al., 2002). An on-line 2-D CE system consisting of CIEF/capillary gel 
electrophoresis (CGE) was also introduced (Yang et al., 2003). 
IEF/RPLC: C. S. Lee and colleagues have developed and demonstrated a 
system based on CIEF coupled to RP-HPLC (Chen et al., 2003a). Xiao and 
co-workers (2004) used a liquid phase IEF device (Rotofor, Bia-Rad 
Laboratories) in a novel ampholyte-free format followed by RPLC to analyze 
tryptically digested serum sample. Recently, immobilized pH gradient (IPG) 
isoelectric focusing is used as first dimension separation followed by RP-
HPLC (Cargile et al., 2005). An important advantage of using IPG technology 
over other IEF formats such as liquid IEF is that the pH gradient in the 
manufactured strips is known and highly reproducible, making prediction of 
the pI range of a particular fraction relatively straightforward (Cargile et al., 
2005). 
SDS-PAGE/RPLC and RPLC/SDS-PAGE: Simpson and co-workers have 
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developed a method, in which the membrane proteins were separated by 
SDS-PAGE in the first dimension. The unstained gel was cut into slices, 
digested and then analyzed by RP-HPLC in the second dimension (Simpson 
et al., 2000). In another study, proteins obtained from whole yeast cell extracts 
were fractionated by HPLC, and the resulting fractions were subjected to 
SDS-PAGE separation (Oda et al., 1999).  
 
1.1.3.2.2. Three-dimensional approaches 
In the past, various technologies have shown promise as alternatives to 2-DE 
in terms of resolution and high-throughput in proteomics. With the emergence 
of the combination of nano-flow high-performance capillary LC–MS, attention 
is now being refocused on utilization of multi-dimensional liquid-phase based 
separation of proteins (Neverova and van Eyk, 2005). In cases where 2-D LC 
approaches do not give satisfactory results, a third orthogonal separation 
procedure, e.g. SCX, is used which would result in the increased resolution of 
a larger number of peptides.  
  Different approaches have been developed such as IEF/SCX/RP (Issaq et 
al., 2005), RP/SCX/RP (Hattan et al., 2005), SEC/RP/CZE (Moore and 
Jorgenson, 1995), SEC/SCX/RP (Jacobs et al., 2004), and ICAT/SCX/RP 
(Gygi et al., 2002).  
 
1.1.4. Mass spectrometry  
One of the earliest methods used for protein identification was 
microsequencing by Edman chemistry to obtain N-terminal amino acid 
sequences. Although Edman analysis was used with considerable success for 
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routine protein identification, the method is relatively slow and insensitive 
(Pappin et al., 1995). Now Mass spectrometry (MS) has rapidly replaced 
Edman sequencing for protein identification. The rapid evolution in mass 
spectrometry, which was initiated by the development of the ionization 
techniques like desorption/ionization (MALDI) and electrospray ionization 
(ESI), has led to significant improvements in the central step of a proteomics 
experiment, protein identification (Hirsch et al., 2004).   
 
1.1.4.1. Principles  
Mass spectrometers are based on a combination of three essential 
components: (1) the ion source, which produces ions from the sample protein 
mixture; (2) the mass analyzer, which resolves ionized analytes on the basis 
of their mass/charge (m/z) ratio; and (3) the detector, which detects the ions 
resolved by the mass analyzer. The data are then automatically recorded and 
can be retrieved for manual or computer-assisted interpretation (Figure 4).  
Ion source: The two most commonly used soft ionization techniques 
introduced in the late 1980s (Karas and Hillenkamp, 1988; Fenn et al., 1989), 
matrix-assisted laser desorption/ionization (MALDI) and electrospray 
ionization (ESI), have provided the methods which allow the formation of ions 
with low internal energies and thus without significant loss of sample integrity 
(Guerrera and Kleiner, 2005). One advantage of MALDI over ESI is that 
samples can be used directly without any purification after in-gel digestion 
(Graves and Haystead, 2002) 
Mass analyzer: After ionization, the sample reaches the mass analyzer 
which separates ions by their m/z ratios. Currently four basic kinds of mass 
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analysers are being used: time-of-flight (TOF), ion trap, quadrupole, and 
Fourier transform ion cyclotron resonance (FT-ICR) analyzers. All four differ 
considerably in sensitivity, resolution, mass accuracy and the possibility to 
fragment peptide ions. The combination of ion source, mass analyzer and 
detector is usually determined by the application. 
Protein identification: MS enables protein structural information, such as 
peptide mass or amino acid sequence, to be obtained. Before mass 
spectrometry, proteins are cleaved into peptides at specific, reproducible 
points in their amino acid sequence using chemical agents or proteases. 
Because of its highly reproducible cleavage on the COOH-terminal side of 
arginine and lysine residues, trypsin is the proteolytic enzyme used most often. 
By comparing the masses of peptides obtained from the proteolytic digestion 
of an unknown protein, the peptide mass fingerprint (PMF), to the predicted 
masses of peptides from the theoretical digestion of proteins in a database, 
the protein identity can be determined (James et al., 1994). 
With the use of two sequential mass analyzers (tandem mass spectrometry 
or MS-MS), primary structural analysis of the amino acid sequence can be 
obtained by fragmenting parent peptides into a series of small daughter 
peptides (Biemann and Scoble, 1987). Peptide fragmentation is achieved by 
preferential cleavage of the backbone bond of polypeptides upon collisional 
activation with a gas collision-induced dissociation (CID) (Medzihradszky and 
Burlingame, 1994). From the m/z of these daughter peptides, the sequence of 
























Figure 4. Mass spectrometry technology for proteomics. Two ionization 
techniques are currently used for biomolecules. (a) Electrospray ionization 
(ESI) is used to volatilize and to ionize peptides and proteins from liquid 
samples, (b) Matrix-assisted laser-desorption ionization (MALDI), the analyte 
is evaporated by a pulsed ultraviolet laser into the gas phase. (c) Scheme of a 
MALDI-TOF instrument (d) Scheme of a MALDI-TOF/TOF instrument 




1.1.4.2. Types of MS  
The names of the various instruments are derived from the name of their 
ionization source and the mass analyzer. ESI is most frequently coupled to 
different MS instruments such as ion traps, quadrupole, and hybrid tandem 
mass spectrometers like quadrupole time-of-flight (Q-TOF) instruments. 
MALDI is usually coupled to TOF analysers, which separate ions according to 
their flight time down a field-free tube and measure the mass of whole 
peptides. 
  MALDI-TOF is widely used to identify proteins by peptide mass 
fingerprinting. If proteins cannot be identified by fingerprinting, they can then 
be analyzed by tandem mass spectrometry or MS/MS in which a combination 
of multiple MS analyzers are adopted to perform a multistage mass analysis 
of ions. Common ESI-paired MS/MS are ESI-triple quadrupole, ESI-ion trap, 
and ESI-Q-TOF. MS/MS can also be carried out using MALDI ionization, such 
as MALDI-TOF-TOF and MALDI-Q-TOF. Some new hybrid-MS analyzers are 
also developed recently including Q-ion trap, Q-Q-ion trap, and Fourier 
transform ion cyclotron resonance (FT-ICR) (Yates, 2004). FT-ICR analysers 
operate by trapping ions in a cell with a static magnetic field. This type of 
analyser is the most powerful currently available in terms of mass resolution 
and mass measurement accuracy (Guerrera and Kleiner, 2005). New 
developments are quadrupole ion trap (QLT)-FTICR-MS (Syka et al., 2004) 
and Q-Q-FTICR-MS (Yates, 2004) which may create huge impact on 
proteomics technology.  
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1.1.5. Array-based proteomics 
From a technical point of view, two main types of technological platform are 
currently used for high-throughput proteomics research: MS-based 
proteomics and microarray-based proteomics (Mocellin et al., 2004). More 
recently, various protein-array gives promise to allow rapid interrogation of 
protein activity on a global scale. These arrays may be based on reagents that 
interact specifically with proteins, including antibodies, peptides and small 
molecules (Tyers and Mann, 2003). 
Protein microarray: Unlike DNA microarrays, which provide one measure 
of gene expression (namely RNA levels), there is a need to implement protein 
microarray strategies that address the many different features of proteins that 
can be altered in disease. These include, on the one hand, determination of 
their levels in biological samples and, on the other, determination of their 
selective interactions with other biomolecules, such as other proteins, 
antibodies, drugs or various small ligands (Hanash, 2003). However, the main 
challenges of this approach are the lack of availability of antibodies, lack of 
purified recombinant proteins, and potential cross-reactivity with affinity agents 
(Baak et al., 2005).  
Fluorescence resonance energy transfer (FRET): Interaction between 
two proteins can be imaged by detecting FRET between donor and acceptor 
fluorescent tags attached to the interacting proteins, which takes place 
nonradiatively (Wouters et al., 2001). FRET monitors macromolecular 
interactions and resolves the spatial and temporal dynamics of protein-protein 


















Figure 5. Scheme of fluorescence resonance energy transfer (FRET). 
Interactions between two proteins can be imaged by detecting FRET between 
donor and acceptor fluorophores. Excitation of a donor fluorophore in a FRET 
pair leads to quenching of donor emission and in an increased, sensitized, 
acceptor emission (Wouters et al., 2001). 
 
 
Surface-enhanced laser desorption/ionization (SELDI): SELDI is an 
affinity-based mass spectrometry method in which proteins (<20 kDa) are 
selectively absorbed to a chemically modified surface (bait), and impurities 
are removed by washing with buffer. The baits are comprised of standard 
chromatographic supports which can be hydrophobic, cationic, anionic, or 
normal phase; or biochemical molecules which can be purified proteins, 
ligands, receptors, antibodies, enzymes, or DNA oligonucleotides (Issaq et al., 
2002b). The proteins that have interacted with the bait surface are then 
analyzed by MALDI-TOF-MS. SELDI is advantageous for rapid screening of 
minute samples, e.g. body fluid obtained from patients can be analyzed for 
differences in protein profiling (Merchant and Weinberger, 2000).  
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1.1.6. Applications of proteomics  
Proteomics deals with three fundamental biological issues: protein 
characterization (including single protein identification and/or quantification 
and sample protein profiling), protein–protein interactions (how proteins work 
together to build up metabolic and signaling pathways), and posttranslational 
modifications of proteins (how protein function can be activated, silenced or 
modulated). Depending on the aim of the research, two main categories of 
proteomics studies can be identified; namely, expression proteomics and 
functional proteomics (Mocellin et al., 2004). 
 
1.1.6.1. Expression proteomics 
Expression proteomics, also called quantitative proteomics, addresses the 
issue of protein expression levels in a given sample, such as a tumor, normal 
tissue or body fluid; this approach is particularly useful for protein profiling 
studies aimed at determining the difference between normal and diseased 
tissues. The protein profile (or ‘signature’) of disease should allow 
investigators to identify disease markers and, ultimately, disease-specific 
and/or patient-tailored molecular targets for the development of effective 
drugs. 2D-PAGE is still the most commonly used approach for protein 
separation which can provide quantitative information directly in the gels. The 
lack of quantitative information limits the use of LC-based approaches in the 
quantitative proteomics. MS itself is relatively poor quantitative device 
because in MS the amount of analyte in the sample does not correlate directly 
with the ion-current intensity of its MS signal (Hirsch et al., 2004; Mocellin et 
al., 2004; Guerrera and Kleiner, 2005). The use of isotope-labeling techniques, 
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such as ICAT, can overcome this shortage. In addition, array-based 
techniques such as SELDI are also alternatives to 2D-PAGE.  
Another development is the use of MALDI-TOF MS in profiling and imaging 
proteins directly from thin tissue sections, a technology known as protein 
profiling and imaging mass spectrometry (IMS) (Chaurand et al., 2004). IMS 
provides specific information on the local molecular composition, relative 
abundance and spatial distribution of peptides and proteins in the analyzed 
tissue section, and can be used as a tool for the investigation of cellular 
processes in both healthy and diseased tissues (Yanagisawa et al., 2003).  
 
1.1.6.2. Functional proteomics  
Functional proteomics includes the analysis of protein-protein interactions, 
protein-non-protein (e.g. DNA, RNA or lipids) interactions and protein 
posttranslational modifications, which will help researchers to dissect the 
complex network of molecular pathways underlying cellular activities in health 
and disease. These types of data should greatly improve our understanding of 
the biological process of disease development and progression, thus fostering 
the identification of not only single protein-specific therapeutic targets but also 
pathway-specific targets (Mocellin et al., 2004).  
  Protein interactions: Three main techniques are used to study protein 
interactions: protein microarrays, co-purification (immunoprecipitation) and the 
yeast two-hybrid system (Mocellin et al., 2004). In immunoprecipitation, the 
protein complex is pull down by corresponding antibody and then separated 
by SDS-PAGE for MS analysis. Unfortunately, there are currently no 
comprehensive antibody collections and many available antibodies do not 
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immunoprecipitate well or lack sufficient specificity. A more generic strategy is 
to ‘tag’ the proteins of interest, for instance, with a sequence that is readily 
recognized by an antibody specific for the tag. This facilitates 
immunoprecipitation of the target-protein complex and its subsequent MS-
based analysis. On the contrary, array-based technologies are undergoing 
rapid development and provide a high-throughout approach to detect the 
interactions of protein with other molecules including proteins, DNA, enzyme 
substrates and so on.    
  Protein modifications: Protein post-translational modifications (PTMs) are 
important information complementary to protein abundances. A protein that 
has experienced some form of post-translational modification exhibits a mass 
increase or decrease relative to the molecular weight calculated from its 
amino acid sequence, which can be detected by MS. Recently, attempts have 
been made to define modifications on a proteome-wide scale by employing 
some form of affinity selection to purify the subproteome’ (e.g. the 
phosphoproteome) bearing this modification. Anti-phosphoserine and anti-
phosphothreonine antibodies (Gronborg et al., 2002), immobilized metal 
affinity chromatography (IMAC) (Nuhse et al., 2003) have been used to enrich 








1.1.7. Proteomics in asthma 
Allergic asthma is a chronic disease which is characterized by chronic airway 
inflammation, airway hyperresponsiveness (AHR) and airway obstruction 
(Busse et al., 2003). Pathologies of airway remodeling are complex involving 
the interaction of many cell types and mediators (Figure 6). To better 
understand the underlying mechanisms, a thorough and global study of the 
function and interaction of different proteins present in the asthmatic airway is 
required and necessary. However, the most abundantly studied respiratory 
disease using proteomics is lung cancer (Houtman and van den Worm, 2005). 
Not until recently has proteomics gained more and more attention emerged as 
a powerful tool for large-scale protein studies of complex diseases such as 
asthma. Analysis of the airway and lung phenotypes of the different stages of 
asthma at the proteome level has great potential for the development of new 
therapeutic strategies.  
  Bronchoalveolar lavage (BAL) fluid has been used in diagnosis and 
research of several inflammatory lung diseases, including emphysema, 
pulmonary fibrosis, cystic fibrosis, pulmonary transplantation and acute lung 
injury for many years (Hermans and Bernard, 1999). BAL fluid contains a wide 
variety of cellular and protein components of the epithelial lining fluid of the 
airways and alveoli. Distinct change in certain protein levels in BAL fluid has 
been correlated to allergic airway inflammation. Many investigations have 
been performed to build a 2D-PAGE database of human BAL fluid proteome 
(Noel-Georis et al., 2002; Wattiez et al., 1999; 2000). Lindahl and co-workers 
(Lindahl et al., 1999) found five previously unidentified protein spots, lipocalin-


















Figure 6. Pathogenesis of asthma showing the interplay among inflammatory 
cells such as T cells, B cells, eosinophils, mast cells and APCs, and airway-
resident cells such as airway smooth muscle cells, epithelial cells, fibroblasts, 
and of their secreted products including cytokines, chemokines, growth 









albumin, which were significantly reduced in the nasal lavage and BAL fluid of 
asthmatic patients. Wu and co-workers (2005) used LC-MS/MS approach to 
analyze the proteome change in human BAL fluid after segmental allergen 
challenge and identified about 160 proteins. However, the high discrepancies 
in the data from these studies maybe due to small number of samples, 
heterogenous disease conditions, and complex environmental factors make it 
difficult to interpret the findings obtained from human samples. For instance, 
only 4 patients with mild asthma and 3 healthy control subjects were recruited 
in Wu’s study. A large scale proteomic investigation using recognized standard 
for subject selection and experimental design is still lacked. Because patient 
material is usually very limited from asthmatic subjects in contrast to cancer 
tissues, using animal models of asthma is a preferred choice for basic 
discovery research. Fajardo and co-workers (2004) reported a group of 
hypoxia-sensitive proteins in C57BL/6 mice BAL fluid which was increased 
after ovalbumin (OVA) sensitization and challenge. In line with our study, they 
also identified Ym1, Ym2 and annexin A3. Signor and co-workers (2004) have 
compared the BAL fluid proteome from rats challenged with OVA and 
challenged with endotoxin (LPS). They have identified some highly abundant 
proteins which were also identified in our study including surfactant proteins, 
α-1-antitrypsin, haptoglobin, transthyretin and annexin A5. Although due to the 
differences in animal species and experiment protocols, their findings differed 
from each other, a higher extent of accordance have been shown in these 
studies in animal than the studies in human. The consistency also validates 
the advantages of animal models in asthma research, e.g. availability of large 
amount of samples and homogeneity of genetic background.  
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  In addition to BAL fluid, lung tissue is also an important sample to study. 
Aulak et al studied nitrated proteins in rat lungs during inflammatory challenge 
(Aulak et al., 2001). Houtman reported lung proteome alterations in a mouse 
model for nonallergic asthma in which BALB/c mice were sensitized with 
dinitro-fluorobenzene (DNFB) (Houtman et al., 2003). However, this study 
showed a totally different spectrum of proteins from what we have found which 
may suggest the development of atopic and nonatopic asthma have different 
mechanisms. A group from Korean reported 15 proteins that were differentially 
expressed in the lungs of BALB/c mice sensitized and challenged with OVA 
(Jeong et al., 2005). 5 of 15 proteins in that study were also found in our study 
including transthyretin, Ym1, Ym2 and ferritin light chain. However, the animal 
models in these studies are all acute asthma models in which only short time 
but high dose exposure to aerosolized antigen is involved. These acute animal 
models are now well recognized that they cannot successfully demonstrate 
airway structural alterations.  
A few additional proteomics studies targeting at single cell type derived from 
either primary cell culture or cell line culture (Westergren-Thorsson et al., 2001; 
Malmstrom et al., 2003; Rosengren et al., 2005) have been reported. Besides, 
proteomics offers a straightforward strategy for the identification of new 
allergens and new IgE-binding proteins (Yu et al., 2003; Fujimura et al., 2004; 






1.2. Asthma  
 
1.2.1. Pathophysiology of asthma 
Asthma has represented a serious threat to human health throughout the 
world. Over the past 25 years, both the prevalence and severity of asthma, 
including mortality, have risen substantially (Corry, 2002). Considering current 
prevalence (150 million affected individuals) and its annual percentage 
increase, it is estimated that by 2010 asthma will affect 300 million people 
worldwide (Torres et al., 2005). Asthma is a disease that is difficult to manage 
pharmacologically because current treatment does not resolve the disease 
and is fundamentally aimed at counteracting episodes of bronchospasm and 
controlling the underlying inflammation in the chronic process, a phase of the 
disease that presents particular therapeutic difficulty (Torres et al., 2005). Thus 
understanding the potential novel mechanisms underlying the development of 
asthma becomes extremely important and urgent.  
 
1.2.1.1. Airway inflammation  
Airway inflammation has been widely demonstrated in all forms of asthma, 
and an association between the extent of inflammation and the clinical 
severity of asthma has been demonstrated in many studies (Bousquet et al., 
2000). The events that occur after allergen inhalation into the airways of 
allergic subjects have been studied extensively. Allergen inhalation results in 
the development of acute bronchoconstriction (the early asthmatic response) 
during 2 hours and delayed bronchoconstriction response (the late asthmatic 
response) with maximum bronchoconstriction between 6 and 8 hours after 
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allergen inhalation and persisting for up to 24 h (Babu and Arshad, 2001; 
O’Byrne et al., 2004). 
 
1.2.1.1.1. Early response and late response  
The early-phase reaction is initiated by the activation of cells bearing allergen-
specific IgE receptors, especially mast cells (Bousquet et al., 2000). 
Circulating IgE is captured by high-affinity IgE receptors (FcεRI) present on 
mast cells/basophils. Exposure to antigens induce FcεRI cross-linking, which 
results in mast cell degranulation and release of a variety of mediators such 
as cysteinyl-leukotrienes (CysLTs), prostaglandins, platelet activation factor,  
histamine, and bradykinin. These mediators cause vascular dilation, 
increased permeability and attract cells into the tissue, thus leading to 
inflammation. The immediate effects on the bronchial trees include 
bronchoconstriction and increased bronchial responsiveness (Busse and 
Lemanske, 2001).  
  A few hours after the allergen exposure, events initiated during the early 
response result in accumulation of inflammatory cells, mucus hypersecretion, 
and oedema formation. Mast cells release cytokines such as IL-3, IL-4, IL-5 
and IL-6 which activate T and B lymphocytes, stimulate mast cells and attract 
eosinophils, further augmenting the allergic reaction. Eosinophils, 
lymphocytes, mononuclear cells, and neutrophils are also involved in this 
stage (Nabe et al., 2005). Eosinophil has been shown to be essential for the 
development of late response (Cieslewicz et al., 1999). Upon activation, 
eosinophils release pre-formed and newly synthesized mediators such as 
eosinophilic cationic protein (ECP), major basic protein (MBP), leukotrienes, 
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and postglandins. These and other mediators enhance inflammation and 
cause epithelial damage. Further secretion of a host of cytokines, including IL-
3, IL-4, and IL-5, contribute to an ongoing inflammation leading to prolonged 
mucus secretion and persistent bronchial hyperresponsiveness.  
 
1.2.1.1.2. Chronic inflammation  
With continued or repeated exposure to allergen, a state of chronic 
inflammation persists, essentially a continued late-phase reaction. This 
inflammatory reaction, however, is not solely IgE-dependent and other 
mechanisms exist which may lead to a similar inflammation state. All cells in 
the airways, including T-cells, eosinophils, mast cells, macrophages, epithelial 
cells, fibroblasts, and even bronchial smooth muscle cells are involved in the 
pathogenesis of asthma and become activated to synthesize proinflammatory 
cytokines and chemokines (Bousquet et al., 2000).  
T helper cell type 2 (Th2): Studies during the past years have revealed the 
central role of the Th2 cells in the setting of allergic inflammation (Pascual and 
Peters, 2005). The Th2 cells secrete a highly characteristic cytokine repertoire 
that includes interleukin-4 (IL-4), IL-5, IL-9, and IL-13, all of which contribute 
to the various manifestations of allergic inflammation and disease (Barrios et 
al., 2006), among which IL-4/IL-13 are essential for B cell activation and 
immunoglobulin isotype switch from IgM to IgE; IL-5 is pivotal for the growth, 
differentiation, recruitment and survival of eosinophils (Renauld, 2001). There 
is evidence of increased numbers of activated Th2 cells in asthmatic airways 
which express IL-3, IL-4, IL-5, and GM-CSF (Bousquet et al., 2000; Pascual 
and Peters, 2005). These cytokines are important in the continuation of 
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inflammation and the attraction of inflammatory cells including eosinophils, 
mast cells and macrophages.  
The relationship between Th1/Th2 cytokines imbalance and asthma has 
been well established and supported by numerous studies. Atopic disease is 
associated with a shift in immune responses away from a Th1 (IFN-γ) pattern 
toward a Th2 (IL-4, IL-5, and IL-13) profile (Busse and Rosenwasser, 2003). 
The importance of Th2 cytokines in asthma has been well recognized. 
However, the therapeutic trials targeting at IL-4 and IL-5 using different 
approaches have not yet proven to be successful in the treatment of 
persistent asthma (O’Byrne at al., 2004). Although this information can not 
exclude the importance of these cytokines, people are starting to reassess the 
Th2 hypothesis in asthma. In fact, the predominant view that Th1 cytokines 
are down-regulated in asthma is somewhat controversial. Decreased allergen-
induced IFN-γ production has been shown to be an important factor 
contributing to ongoing severe asthma (Smart et al., 2002; Busse and 
Rosenwasser, 2003). However, other studies have demonstrated that 
increases in serum IFN-γ levels (Litonjua et al., 2003) or in T-cell IFN-γ 
production in cell cultures (Koh et al., 2002) in asthmatics are associated with 
a greater decline in lung function. In addition, the levels of IFN-γ-producing T 
cells are increased in the airways of atopic asthmatic children and adults 
(Brown et a., 2003) and allergen-specific stimulation of T cells from atopic 
children increases both Th1-type (IFN-γ) and Th2-type cytokines (IL-5 and IL-
13) (Smart and Kemp, 2002).  
  Eosinophils: Eosinophils play an important effector role in asthma by the 
release of proinflammatory mediators, cytotoxic mediators, growth factors, 
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and cytokines. Intraepithelial eosinophils are a distinctive feature of asthmatic 
airway inflammation and numerous eosinophils are also present within the 
airway wall (Kumar, 2001). Most allergic and nonallergic asthmatics, including 
those with mild asthma, have a bronchial eosinophilia and there is a 
significant association between eosinophil activation and asthma severity as 
well as bronchial hyperresponsiveness (Bousquet et al., 2000). Once 
activated, products from eosinophils contract human bronchial smooth muscle 
increase vascular permeability, and induce airway hyperresponsiveness. 
Eosinophils are deleterious in asthma by the release of highly toxic products 
(major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil-
derived neurotoxin (EDN), and oxygen free radicals) which induce the 
shedding of the surface epithelium of the airways (Moqbel, 1996; Bousquet et 
al., 2000; Wolthers, 2003). 
  Neutrophils: Neutrophils are recruited in acute inflammation of the airways 
in mild to moderate asthma, but appear to play a relatively minor role (Norzila 
et al., 2000). Kelly and co-workers (1988) showed a correlation between the 
numbers of neutrophils and airway hyperresponsiveness, and the activity of 
neutrophils was increased in asthmatic subjects compared with control 
subjects. They may have more significance in severe form of asthma that may 
be fatal. In addition, during an exacerbation of asthma, a marked increase in 
neutrophils has been observed in sputum (Turner et al., 1995). Some other 
reports confirmed the elevated neutrophils in airway mediated by IL-8 in 
persistent, refractory asthma without eosinophilia (Gibson et al., 2001). 
Cell recruitment and survival in the airway: The inflammatory cells 
pertinent to airway inflammation are generated in the bone marrow. They then 
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transit through the circulation and migration rapidly into tissues. Endothelial 
cells have a major role in inflammatory cell recruitment into the airway 
submucosa (Luscinskas and Gimbrone, 1996). There is up-regulation of 
intracellular adhesion molecules in the blood vessels promoting stickiness of 
the endothelium to leukocytes and facilitating their passage across into the 
tissues. The transmigration of inflammatory cells is a multi-step process 
involving the interaction of a group of adhesion molecules. Rolling along 
vessel wall is the first step which is mediated by selectins. Firm adherence of 
cells to endothelium is the second step and involves other adhesion 
molecules such as CD11a, CD11b, CD18, or very late activation antigen 
(VLA-4) on leucocytes and intracellular adhesion molecule (ICAM)-1 or 
vascular cell adhesion molecule (VCAM-1) on endothelial cells (Bochner, 
2004; Vanderslice et al., 2004). Up-regulation of these adhesion molecules in 
allergic inflammation is critical for the induction of the inflammatory response 
(Bousquet et al., 2000).  
  Recruitment of cells into the airways is also dependent on cytokines, such 
as IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF), 
which act on eosinophil recruitment, maturation, and increased survival. 
Chemokines such as RANTES (regulated upon activation, normal T cell 
expressed and secreted) and eotaxin also act on eosinophils and T cells to 
enhance their recruitment (Lukacs, 2001; Schuh et al., 2003). In addition to be 
potent leucocyte chemoattractants, chemokines are also cellular activating 
factors and histamine-releasing factors, which makes them particularly 
important in the pathogenesis of allergic inflammation (Zimmermann et al., 
2003). In particular, the eotaxin subfamily of chemokines and their receptor 
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CC chemokine receptor 3 have emerged as central regulators of the 
asthmatic response. 
   
1.2.1.2. Airway remodeling 
Airway wall remodeling refers to a series of progressive structural changes in 
the airway wall (Barrios et al., 2006). These changes most likely occur as a 
result of repeated episodes of inflammation with production of matrix proteins 
and growth factors by inflammatory cells. It is also possible that repeated 
damage to the epithelium, with subsequent repair, may lead to airway 
remodeling. Airway remodeling in asthma includes not only structural changes 
but also fundamental changes in the relationships between and among 
various airway constituents. Cell-cell interactions, the regulation of cells by 
extracellular matrix, and the modulation of the composition of matrix by cells 
have all been demonstrated to be altered (Pascual and Peters, 2005).  
 
1.2.1.2.1. Characteristics of airway remodeling  
Changes during airway remodeling involving epithelial goblet cell hyperplasia 
and metaplasia, collagen deposition and thickening of the lamina reticularis, 
smooth muscle hyperplasia, and proliferation of airway blood vessels and 
nerves are consistently observed in ongoing disease, as well as in 
postmortem asthmatic airways (Davies et al., 2003).  
Mucus hypersecretion: Mucus production is an important feature of 
asthma and contributes substantially to morbidity and mortality, especially in 
more severe disease (Cohn, 2006). Many case reports and autopsy series 
demonstrate that in most cases of fatal asthma, many of the small airways are 
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completely obstructed with mucus (Bousquet et al., 2000). In asthma, 
epithelium is partly shed, ciliated cells appear swollen, and there is often loss 
of cilia (Montefort et al., 1993). In fatal asthma, extensive epithelial shedding 
is commonly observed (Bousquet et al., 2000) When epithelium is 
reconstituted, there are greater numbers of goblet cells than in normal 
epithelium. Goblet cell hyperplasia has been consistently demonstrated in 
asthma, irrespective of whether the disease is mild or severe (Pascual and 
Peters, 2005). Similarly, enlargement and hyperplasia of mucus glands found 
in the subepithelium is also a frequent finding. Goblet cells and mucus glands 
are the sources of mucin glycoproteins in the airways (Bousquet et al., 2000). 
Epidermal growth factor receptor (EGFR) and IL-13 have been showed to be 
necessary in a two-step model leading to metaplasia of ciliated epithelial cells 
into goblet cells and overproduction of mucus in chronic asthma (Tyner et al., 
2006). Sixteen genes encoding for human mucins are currently recognized. 
Currently, the gene products for MUC5AC and MUC5B are considered the 
major mucins in airway secretions from normal subjects and from patients with 
asthma or COPD (Kim et al., 2003). MUC5AC is considered the major goblet 
cell mucin, with MUC5B the major submucosal gland mucin, but which is also 
present in goblet cells (Rogers, 2003). Myristoylated alanine-rich C kinase 
(MARCKS) is another key molecule regulating mucin exocytosis, a process 
also involving cooperative interaction between protein kinase (PK) C and PKG 
(Rogers, 2003).  
Airway smooth muscle remodeling: Smooth muscle mass is usually 
increased in large and/or small airways in both fatal and nonfatal cases of 
asthma (Bousquet et al., 2000). Patients dying of status asthmaticus have a 2-
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fold to 3-fold increase in the amount of airway smooth muscle (ASM) in 
asthmatic airways by comparison to normal subjects (Barrios et al., 2006). 
Several possible mechanisms could explain this finding: an increase in cell 
number (hyperplasia) resulting from increased cell proliferation or a reduction 
in apoptosis, cellular hypertrophy, and/or differentiation of other cell types into 
ASM cells, with subsequent migration into the muscle bundle (Pascual and 
Peters, 2005).  
Majority of the available evidence supports ASM hyperplasia as an 
important mechanism leading to increased ASM mass in the asthmatic airway 
(Pascual and Peters, 2005). Many molecules can stimulate the proliferation of 
airway smooth muscle and affect ASM mass, such as EGF, transforming 
growth factor (TGF)-β, leukotriene (LT) D4, LTE4, IL-1β, and tumor necrosis 
factor (TNF)-α (Hirst et al., 2004). Mitogenesis mediated by cytokines, 
receptor tyrosine kinase ligands, and G protein–coupled receptor ligands 
occurs through the phosphoinositide 3’-kinase (Page et al., 2000) or the 
mitogen-activated protein kinase (MAPK) pathways (Orsini et al., 1999). 
Cumulative evidence suggests that combinations of ligands can induce ASM 
proliferation in vitro in a synergistic manner (Krymskaya et al., 2000). On the 
other hand, there are also reports showing the ASM hypertrophy in asthmatic 
autopsied airway (Ebina et al., 1993; Benayoun et al., 2003). Several 
mediators are known to increase smooth muscle size including TGF-β, IL-1, 
IL-6 and angiotension II (Stewart, 2001).  
It has been proposed that myofibroblasts play a role in this smooth muscle 
thickening and also in the reticular basement membrane thickening. Exposure 
of the epithelium to allergen causes myofibroblasts to migrate toward the 
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smooth muscle or that smooth muscle cells migrate from the muscle bundles 
toward the lamina reticularis in response to myofibroblast-derived 
chemoattractants (Gizycki et al., 1997). Because myofibroblasts have a 
phenotype that is essentially an intermediate between that of the fibroblast 
and the smooth muscle cell, this raises the possibility that myofibroblasts 
might contribute directly to increased smooth muscle mass because of their 
phenotypic plasticity (Davies et al., 2003).  
The effect of changes in ASM mass on airway resistance remains under 
investigation. Intuitively an enhanced contractility is expected based on 
increased ASM mass. However, in vitro studies have not consistently showed 
that asthmatic ASM generates more force or becomes more sensitive to 
constrictor agonists than normal ASM (Dulin et al., 2003). Another interesting 
hypothesis is that airway wall thickening in asthmatic subjects results in a 
greater reduction in luminal cross-section when normal force is applied 
(Solway and Fredberg, 1997). Deng and co-workers (2005) raise a possibility 
of a maladaptive positive feedback in asthma in which enhanced ASM tone 
potentiates ASM remodeling and stiffening that, in turn, further increases 
stress, thus forming a vicious cycle of worsening airway function. 
Another hypothesis is that in response to allergen challenge in asthma, 
there is de-differentiation of existing smooth muscle myocytes (the cells then 
are best referred to as “fibromyocytes”), and the cells migrate to a 
subepithelial site where they form new muscle of abnormal phenotype and 
abnormal function (Jeffery, 2004). However there are not enough data to 
support this hypothesis yet.  
In addition to their contractile function, ASM has been shown to be involved 
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in regulating immune response through the release of several mediators, 
including cytokines, chemokines, and growth factors (Joubert and Hamid, 
2005).  
Subepithelial fibrosis: The basement membrane underlying the bronchial 
epithelial cell layer is composed of several layers: the basal lamina (referred 
to as the ’true’ basement membrane) and the lamina reticularis (reticular 
basement membrane, RBM) (Bousquet et al., 2000). Electron microscopy 
demonstrated that the true basement membrane, the lamina rara and densa, 
is normal in asthma. The “thickening” is the result of a dense fibrotic response 
that occurs primarily in the lamina reticularis (Elias et al., 1999). Subepithelial 
fibrosis is a distinctive feature of airway remodeling and contributes to the 
thickened airway walls due to the deposition of collagen types I, III, and V, 
fibronectin, and other extracellular matrix (ECM) proteins such as tenascin 
and laminin (Humbles et al., 2004).  
The pathophysiologic significance of subepithelial fibrosis is not clear. An 
association between RBM thickness and FEV1 in adult asthma has been 
described by some investigators (Chetta et al., 1997; Kasahara et al., 2002) 
but not by others (Chu et al., 1998; Payne et al., 2003). Payne and co-workers 
(2003) compared the thickness of the RBM in asthmatic children with that in 
healthy children and adults with asthma. Interestingly, the thickness of the 
RBM in asthmatic children was similar to that in asthmatic adults and nearly 
twice as thick as that in control children, indicating that this feature of airway 
remodeling occurs early in the course of asthma. 
Blood vessels: Airway wall remodeling in asthma patients involves a 
number of changes, including increased vascularity, vasodilatation, and 
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microvascular leakage (Vignola et al., 2003b). Evidences suggest that 
angiogenesis occurs in chronic asthma, and the number and size of bronchial 
vessels are moderately increased in patients with asthma compared with 
normal controls (Salvato, 2001).  
 
 
1.2.1.2.2. Mechanism of airway remodeling  
The mechanisms underlying the airway remodeling is still unclear. Although 
remodeling has been commonly considered as a consequence of repeated 
long-standing inflammation (Elias et al., 1999), airway biopsy studies in young 
children have shown tissue remodeling occur early in the course of the 
disease, indicating that this process begins early in the development of 
asthma and might occur in parallel with inflammation or even be required for 
the establishment of persistent inflammation (Pohunek et al., 2005). The 
structural alterations in airway are poorly responsive to corticosteroid which is 
considered the most effective anti-inflammatory agent for asthma. Although 
prolonged steroid therapy can greatly relieve airway hyperresponsiveness, the 
airway remodeling is difficult to be completely reversed (Gono et al., 2003; 
van den Toorn et al., 2003). That suggests that there are other mechanisms 
existing in the process of airway remodeling independent on airway 
inflammation. Airway remodeling may provide a possible explanation for 
corticosteroid-resistant AHR and the accelerated decline in lung function 
observed over time in adult asthma (Davies et al., 2003).  
  Eosinophil: Eosinophils are prominent in the airways of patients with 
asthma (Bousquet et al., 2000). As effector cells, eosinophils are capable of 
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producing Th2 cytokines, chemokines, lipid mediators, and growth factors and 
are also capable of causing an increase in mucus production, causing 
subepithelial fibrosis, and altering ASM contractility (AHR) (Pascual and 
Peters, 2005). However, whether eosinophils play a central in airway 
remodeling and AHR is still controversial. Two recent studies which generated 
eosinophil-deficient mice using different transgenic strategies show different 
results. The Δdb1 GATA mice showed markedly decreased matrix deposition 
and airway smooth muscle hyperplasia, but not mucus hypersecretion, AHR, 
IL-4/IL-5 levels, IgE level, and Th2 cell number in the airways (Humbles et al., 
2004). On the other hand, PHIL mice were completely protected from 
developing AHR and showed partial protection from airway mucous 
metaplasia (Lee et al., 2004). That suggests that different components of 
airway remodeling may have distinct mechanisms.  
  Epithelium-Mesenchymal Interactions: The airway epithelium plays an 
important role in the pathogenesis of airway remodeling. In asthmatics, the 
bronchial epithelium is highly abnormal, with structural changes involving the 
separation of columnar cells from their basal attachments, and functional 
changes including increased expression and release of pro-inflammatory 
cytokines, growth factors, and enzymes (Vignola et al., 2003b). Injury of the 
epithelium in allergic airway inflammation results in a localized and persistent 
increase in EGFR in areas of damage (Lazaar and Panettieri, 2003). During 
repair, epithelia also release other pro-fibrotic mediators such as TGF-β, 
fibroblast growth factor and endothelin, which can directly regulate the 
phenotypic and functional features of mesenchymal cells that are located 
underneath the basement membrane, such as smooth muscle cells, 
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fibroblasts and myofibroblasts (Davies et al, 2003). Under the effects of 
epithelial-derived growth factors, mesenchymal cells produce collagen, 
reticular and elastic fibers, as well as proteoglycans and glycoproteins of the 
amorphous ECM, all of which likely contribute to the thickened airway wall in 
asthmatic subjects (Vignola et al., 2003b).  
 
  Proteases and Protease Inhibitors: Matrix metalloproteinases (MMPs) 
are key regulators of the components of matrix and regulate the deposition of 
collagen and cytokine release (Pascual and Peters, 2005). MMPs selectively 
degrade ECM components. Tissue inhibitors of metalloproteinases are 
endogenously expressed inhibitors of metalloproteinases and exist in 
equilibrium with the metalloproteinases in the airway wall. Although the 
mechanism is still under investigation and not accurately known, the 
imbalance between MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-
1) is considered a major theory to explain the progression of asthmatic airway 
remodeling (Gueders et al., 2006). Various inflammatory cytokines including 
TGF-β and growth factors play a pivotal role in MMP-9 production and 
secretion (Ohbayashi and Shimokata, 2005). On the other hand, MMP-9 was 
showed to be involved in mediating the effect of IL-13 on TGF-β production 
(Lee et al., 2001). Matrix metalloproteinase inhibitor regulates inflammatory 
cell migration by reducing ICAM-1 and VCAM-1 expression in a murine 
asthma model (Lee et al., 2003). An additional mechanism regulating smooth 
muscle proliferation is represented by the production of MMP-2, which has 
been demonstrated to be an important autocrine factor that is required for 
airway smooth muscle proliferation (Johnson and Knox, 1999).  
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1.2.2. Animal models 
Animal models of asthma have contributed abundantly to the understanding of 
the pathophysiologic mechanisms of asthma. Accordingly, they are of great 
value for the development and preclinical evaluation of new chemical entities 
in the search for new drug therapy. Various animal models including guinea 
pigs, monkeys, dogs, rats, mice, hamsters, rabbits, dogs, sheep, horses and 
non-human primates have been established in an attempt to provide insights 
into the complex immunological and pathophysiological mechanisms of 
human allergic diseases (Herz et al., 2003). An ideal animal asthma model 
should resemble the major features of the human disease including high 
levels of allergen-specific immunoglobulin production, airway inflammatory 
infiltration, airway hyperresponsiveness, and chronic airway remodeling with 
deterioration in lung function. The non-human primates may be the perfect 
animal models of asthma from an anatomical point of view. They are also 
considered to have a similar immune system to that of humans compared with 
mice, rats, and guinea pigs. Most features of asthma have been demonstrated 
in monkeys (Szelenyi, 2000). However, due to economic and ethical reasons 
non-human primates are rarely used in asthma research. Among other 
species, mice are increasingly being used for asthma research given the 
obvious advantages. Firstly, the mouse is a non-endangered species that 
offers wide availability of genetically characterized inbred strains at relatively 
low cost. Secondly, this species allows for the application in vivo of an 
extremely wide diversity of immunological tools, including genetic 
manipulation (transgenic and knockout) and wide availability of immunological 
reagents (Kips et al., 2003; Torres et al., 2005). Murine models can provide 
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some major characteristic features of asthma such as airway and lung tissue 
eosinophilia, mucus hypersecretion, and AHR (Taube et al., 2004; Epstein, 
2004). However, like other animal species, murine models also have 
limitations. Mice do not spontaneously develop asthma. Because of 
considerable physiological dissimilarities between primates and rodents, 
some of the finding from murine models may be difficult to apply to humans. 
Moreover, in contrast to humans, OVA-induced airway inflammation in BALB/c 
and C57BL/6 mice does not involve significant eosinophil degranulation 
(Malm-Erjefalt et al., 2001). Therefore, apart from the difficulties in transposing 
murine to human data, it has to be borne in mind that mice are probably more 
suitable for modeling a trait associated with asthma, rather than for modeling 
the entire asthma phenotype (Kips et al., 2003).  
Many experimental mouse models of asthma have been proposed. In 
general, the induction protocols are based on systemic sensitization through 
injection of an allergen to generate a memory immune response followed by 
local re-exposure of the respiratory system to the same allergen. Often, during 
sensitization, the allergen is administered along with an adjuvant or a 
nonspecific immunopotentiator compound such as aluminum sulfate (alum) to 
elicit a sufficiently strong immune response (Herz et al., 2003; Torres et al., 
2005). Currently, murine asthma models could be classified into acute allergic 
model and chronic allergic model according to the sensitization/challenge 
protocols. However, each model has its own inherent advantages and 
shortcomings and no model is identical to the conditions found in human 
disease (Tournoy et al., 2006). 
Acute asthma model: For induction of experimental airway allergy, 
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different experimental protocols are being applied by different research groups. 
Most frequently, a biphasic protocol consisting of a systemic sensitization 
phase followed by an airway challenge phase is used for the induction of 
allergen-specific IgE production, bronchial eosinophilia and 
hyperresponsiveness in mice (Hellings and Ceuppens, 2004). The acute 
models can represent most features of acute allergic responses which are 
similar to the early asthmatic responses in humans. Because of their well-
characterized immune system, the availability of research products and 
transgenic mice, mice models are attractive and useful for understanding the 
Th2 immunity, evaluating the functional role of a given cell type or mediator by 
in “knock-out” mice, and testing the therapeutic effects of drugs. However, the 
intensity of such a Th2-biased immune response depends largely on the 
genetic background of the mice, the route, dose and frequency of exposure to 
the allergen, and the type of adjuvant being used in different studies (Table 2) 
(Herz et al., 2004). That variance makes interpretation and comparison of 
results more difficult. More importantly, acute model lacks chronic airway 
remodeling changes including subepithelial fibrosis and smooth muscle 
hyperplasia and hypertrophy, which are the critical features of asthma in 
humans, due to the short-term experiment (Kumar and Foster, 2001; 2002). 
Moreover, very often, high-dose allergen exposure is required for the 
development of acute asthma model, which is not physiologically experienced 





Table 2. Development of allergic responses to allergens, airway inflammation, 





Chronic asthma model: In most chronic mouse asthma models, mucus 
hypersecretion, epithelial cell hyperplasia and thickening of the basement 
membrane were found in the bronchi in response to repeated airway 
challenges with allergens (Temelkovski et al., 1998). Low mass concentration 
of aerosolized allergen is usually used for more than 6 weeks (Kumar and 
Foster, 2002). However, allergen-induced increase in antigen-specific serum 
IgE level and eosinophil number in BAL fluid is frequently subsided in these 
models (Temelkovski et al., 1998; Palmans et al., 2000; Kumar and Foster, 
2001). Some other reports show that prolonged antigen exposure actually 
induced a tolerance response which may involve T cell profile shift 
(Yiamouyiannis et al., 1999; Sakai et al., 2001; Schramm et al., 2004). That 
may partially be attributed to different protocols used and different 
concentrations of allergen in aerosol. Recently, mouse asthma model has 
been used to study immune tolerance. For example, it has been shown that 
oral antigen administration prior to systemic sensitization or prolonged antigen 
challenge without systemic sensitization could induce tolerances (Torres et al., 
2005; Tournoy et al., 2006). However, a study in which the systemic 
sensitization was omitted still demonstrated airway inflammation and 
remodeling (Johnson et al., 2004). Nevertheless, though these chronic 
asthma models may not be able to demonstrate all the chronic features 
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existing in humans, they are still useful in studying some specific aspects 
such as airway remodeling. Meanwhile, physiological similarity makes the 
chronic model a necessary tool for studying chronic asthma. 
Additional experimental techniques that have proved to be particularly 
valuable in studying the pathogenesis of asthma have been the generation of 
knockout or transgenic animals. This approach has proven to be a powerful 
method for defining the function of specific molecules. Studies using 
transgenic and gene-ablated mice in such models have yielded some 
fascinating insights into the pathogenesis of asthmatic inflammation and 
airway remodeling (Torres et al., 2005). However, overexpression of some 
molecules may introduce an artificial situation (kips et al., 2003). Meanwhile, 
due to the large amount of mediators which are involved in the development 
of asthma and functional redundancy of biological molecules, knock-out of 
one target may show no effects on the physiologic changes.   
 
1.2.3. Treatment of asthma 
 
1.2.3.1. Glucocorticoids  
Glucocorticoids (GCs) have been the predominant therapeutic class for mild, 
moderate and severe persistent asthma due to their broad anti-inflammatory 
properties during the past years (Umland et al., 2002). Glucocorticoids exert 
their effects by binding to ubiquitously expressed glucocorticoid receptor (GR), 
a member of the nuclear receptor family. GC-GR complex can recognize 
specific DNA sequences called GC response element (GRE) which is often 
found in the promoter region of target genes, thus directly alters gene 
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transcription. In addition to the direct interaction with DNA, the major anti-
inflammatory effects of GCs occur through protein-protein interaction between 
GR and transcription factors, such as activator protein 1 (AP-1), nuclear factor 
κB (NF-κB), signal transducers and activators of transcription (STAT) proteins 
and cyclic adenosine monophosphate (AMP) response element binding 
(CREB) proteins (Adcock and Caramori, 2001; Umland et al., 2002). These 
factors regulate a number of genes involved in inflammation (Table 3). 
However, the known spectrum of genes which can be regulated by GCs is far 
from complete. In vivo and in vitro studies have suggested both enhancing 
and suppressive effects of GC on the immune and inflammatory response, 
and even more discrepancies have emerged (Galon et al., 2002). 
Unfortunately, long-term administration of glucocorticoids can result in 
multiple adverse effects. Meanwhile, 5% to 10% of asthmatic patients are 
glucocorticoid-resistant and fail to respond to even high doses of oral steroids 
(Ito et al., 2006). That drives scientists to try hard to develop novel drugs 
using genomic screening and combinatorial chemistry in the last decade; 
however, the result is disappointing. With the exception of the leukotriene 
receptor antagonists and some monoclonal antibodies, no new developments 
have been introduced into asthma therapy. Inhaled corticosteroids still remain 
the most effective agents available for the symptomatic control of asthma and 
improvement in pulmonary function (Gibson and Powell, 2006). There is no 
evidence at the very moment showing that corticosteroids can be displaced in 
the next ten years. The most promising approach is still to improve the 
corticosteroids and make therapy with them even safer or find drugs like 
corticosteroids with multiple functions (Amon et al., 2006). Therefore, 
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thoroughly understanding the mechanisms of the action of GCs becomes 
urgent.    
 
 
Table 3. Glucocorticoid-regulated genes (Adcock and Caramori, 2001). CC-10, 
Clara Cell protein 10; MIP, macrophage inflammatory protein; MCP, monocyte 
chemoattractant protein; iNOS, inducible nitric oxide synthase; COX, 
cyclooxygenase; cPLA, inducible phospholipase A2; and NK, Neurokinin. 
 
 
Increased gene transcription 
Lipocortin-1 (annexin-1) 
β2-adrenoceptor 
Secretory leucocyte inhibitory protein, CC-10 
IL-RII, IL-1ra 
IκB-α 
Decreased gene transcription 
Cytokines 
IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-11, IL-13, TNF-α, GM-CSF 
Chemokines  
RANTES, eotaxin, MIP-1α, MCP-1, MCP-3 
Enzymes 












1.2.3.2. Other therapeutic agents 
Currently, short-acting β2-agonists, anticholinergic agents, theophylline, and a 
combination of these drugs are the standard first-line and second-line 
bronchodilators (Buhl and Farmer, 2004). Inhaled short-acting β2-agonists are 
usually the preferred bronchodilators, although some studies suggest that 
anticholinergic bronchodilator drugs have comparable effects on lung function 
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and these agents could be also beneficial in preventing airway remodeling in 
asthmatic airways (Kanazawa, 2006). New developments in this field include 
the long-acting β2-agonists (LABAs) such as salmeterol and formoterol. In 
addition to the long-lasting bronchodilating effect, the LABAs have shown 
synergistic effects with corticosteroids. Potentially important interactions have 
been observed between LABAs and inhaled corticosteroids. Long-acting β2-
agonists may affect GR nuclear localization through modulation of GR 
phosphorylation and furthermore through priming of GR functions within the 
nucleus by modifying GR or GR-associated protein phosphorylation. 
Glucocorticoids in turn may regulate β2-adrenergic receptor function by 
increasing its expression, acting through GREs, and, importantly, by reversing 
β2-receptor down-regulation, thereby preventing desensitization (Adcock et al., 
2002). A synergistic effect on transcription factors and an inhibitory effect on 
smooth muscle cell proliferation have been observed (Roth et al., 2002). 
However, considerable concern remains over the use of LABAs that they may 
mask the underlying airway inflammation (Currie et al., 2005). 
  Leukotriene receptor antagonists (LTRAs) are another group of drugs, such 
as montelukast or zafirlukast, which can be used as add-on therapy for 
patients who remain symptomatic despite inhaled corticoids treatment. LTRAs 
demonstrate bronchodilatory and anti-inflammatory properties in addition to 
an ability to attenuate AHR (Currie et al., 2005). Although it has been about 25 
years after the discovery of leukotrienes, there is still a great need for more 
clinical and translational research into the role of leukotrienes in asthma 
(Dahlen, 2006).   
Improved understanding on the cellular and molecular basis of asthma has 
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identified more potential candidates for drug development. During the past 
few years, several intriguing new approaches to the treatment of asthma have 
been tested. One that appears promising is the administration of a 
recombinant humanized monoclonal antibody to human IgE (Omalizumab). 
Omalizumab administered subcutaneously is an effective treatment for add-on 
therapy in patients with poorly controlled, moderate-to-severe allergic asthma 
and allergic rhinitis and reduces the requirement for inhaled corticosteroids 
while protecting against disease exacerbation (Dodig et al., 2005). There has 
been great acceptance of the use of Omalizumab in asthma practices to 
assist patients achieve better control and reducing exacerbations (Marcus et 
al., 2006). However, despite the demonstration of the efficacy of the drug, 
there have also been skeptics, particularly in terms of the costs of therapy 
compared to the benefits obtained (Marcus et al., 2006). 
  Th2 cytokines such as IL-4 and IL-5 are also attractive targets for potential 
drug development. There are several potential ways of inhibiting cytokine 
effects including blocking antibodies, soluble receptors, altering the balance of 
certain cytokines, and antisense oligonucleotides. Anti-IL-5 mab (monoclonal 
antibody) has been developed but the efficacy is controversial (Corry et al., 
1996; Foster et al., 1996; Leckie et al., 2000; Flood-Page et al., 2003a, b). The 
disappointing findings do not necessarily exclude the usefulness of this 
approach. Anti-IL-5 therapy may only benefit those patients in whom 
eosinophilic inflammation contributes significantly to the signs and symptoms 
of disease (Jonkers and van der Zee, 2005). Similarly, lack of clinic efficacy 
prevents the further development of soluble IL-4 receptor alpha (IL-4Rα) 
(Boushey, 2004). However, human and humanized blocking IL-4 monoclonal 
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antibodies are also currently in clinical development. Interleukin-13 remains a 
highly relevant new target for treatment of chronic severe asthma, utilizing 
either recombinant human IL-13Rα2 receptor as a molecule decoy or blocking 
monoclonal antibodies. Both approaches are in clinical trial (Boushey, 2004). 
Approaches aiming at the inhibition of the IL-4 pathway, such as interrupting 
downstream IL-4 receptor signaling by targeting transcription factors such as 
Stat6 and GATA-3, are also under investigation (Jonkers and van der Zee, 
2005). Some immunostimulatory approaches targeted at the Th1/Th2 balance. 
Using CpG oligodeoxynucleotides (Hussain and Kline, 2001) or recombinant 
IL-12 (Bryan et al., 2000) could induce Th1-polarized immune responses and 
inhibit Th2-mediated eosinophils recruitment. However, it is still a long way to 
go to become a clinically-approved drug.  
  There are some other new targets undergoing extensive investigation from 
both basic research and clinical trial. Evidences have showed that 
thromboxane a2 (TxA2) is involved in the onset and development of allergic 
diseases (Nagai et al., 2006). The efficacy of TxA2 inhibitor in asthma 
treatment is still under discussion, but the effectiveness of TxA2 receptor 
antagonist in allergic rhinitis is noteworthy. Phosphodiesterase-4 (PDE4) is an 
important cAMP-metabolising enzyme in immune and inflammatory cells, 
airway smooth muscle and pulmonary nerves. Selective inhibitors of this 
enzyme show a broad spectrum of activity in animal models of COPD and 
asthma. The drug targeting PDE4 or other PDE families like PDE7A are 




1.3. Rationale and objectives 
Allergic asthma is a chronic airway disorder characterized by airway 
inflammation, mucus hypersecretion, and airway hyperresponsiveness (Elias 
et al. 2003). The prevalence and mortality rate of asthma has been increasing 
worldwide for the past 2 decades. Our current understanding of the 
pathogenesis of asthma is primarily a Th2 cytokine-mediated inflammatory 
disorder, which involves IL-4, IL-5 and IL-13. Nevertheless, strategies targeted 
at these cytokines failed to offer a striking benefit in the treatment of asthma, 
especially in the modulation of airway hyperresponsiveness (Holt et al., 2004; 
O'Byrne et al, 2004). There is an urgent need to identify additional and novel 
therapeutic targets and biomarkers for the management of asthma. 
BAL fluid is routinely collected from patients suffering from a variety of lung 
diseases and from animal models of lung disorders such as asthma, for 
diagnosis and study of pathogenesis (Hermans and Bernard, 1999). BAL fluid 
contains a wide variety of cellular and protein components of the epithelial 
lining fluid of the airways and alveoli. However, proteome analysis of 
asthmatic BAL fluid is lacking so that potentially novel biomarkers and 
pathogenic molecules for asthma remain to be identified. Proteomics is the 
important global protein profiling technique applicable to biologic fluids such 
as BAL fluid, which cannot be analyzed using nucleic acid-based approaches 
(Noel-Georis et al., 2002; Hirsch et al., 2004). The purpose of the first part of 
this study was to employ proteomics technology to analyze and quantify the 
alterations of global protein expression in BAL fluid from mice with acute 
allergic airway inflammation.   
Airway remodelling is postulated to be a critical mechanism in the 
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maintenance and deterioration of chronic asthma, and the process of 
remodelling does not clearly appear to be reversed by current regimen of 
treatments, mainly anti-inflammatory drugs and bronchodilators (Bousquet et 
al., 2000; Fulkerson et al., 2005). Various degree of airway remodeling has 
been shown to present in most patients even when they are asymptomatic 
(Gono et al., 2003; van den Toorn et al., 2003). Recently, several laboratories 
have successfully described chronic murine asthma models with airway 
remodeling and persistent airway inflammation after prolonged challenges 
with low-dose allergen (Temelkovski et al., 1998; McMillan and Lloyd, 2004; 
Shinagawa and Kojima, 2003; Wegmann et al., 2005; Pitchford et al., 2004). 
To better understand the underlying mechanisms of airway remodeling and 
airway inflammation in chronic condition, in the second part of this study, we 
developed a chronic asthma model which replicated several key 
characteristics of asthma, including airway wall inflammatory cell infiltration 
and subepithelial fibrosis. The proteins from lung tissue together with BAL 
fluid from mice were subjected to proteomics analysis.  
  Glucocorticoid is the most effective anti-inflammatory agent for asthma due 
to the widespread anti-inflammatory properties. A great deal of effort has been 
focused on trying to understand the cellular and molecular mechanisms of 
action of GC. In vivo and in vitro studies have suggested both enhancing and 
suppressive effects of GC on the immune and inflammatory response, and 
even more discrepancies have emerged (Galon et al., 2002). Nevertheless, 
the full spectrum of protein targets of glucocorticoid is still not understood. 
Additional, while most patients respond well to conventional antiasthmatic 
therapy, a small percentage, however, are steroid-resistant and difficult to 
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control (Virchow, 2006). The mechanism is unknown. Therefore, a 
comprehensive study of global protein expression in allergic airways in 
response to glucocorticoid therapy is needed. The purpose of the third part of 
this study is to investigate the pharmacological effect of dexamethasone on 
global protein expression in BAL fluid from a mouse asthma model, which 
may ultimately help identify novel protein targets of glucocorticoid and 














































2.1. Mouse asthma models  
 
2.1.1 Acute asthma model 
Male BALB/c mice 6-8 wk of age (Interfauna, East Yorkshire, UK) were 
sensitized by intraperitoneal injections of 20 µg ovalbumin (OVA) (Grade V, 
Sigma, St. Louis, MO) together with 4 mg Al(OH)3 in 0.1 ml saline on days 0 
and 14. On days 18, 19, and 20, animals were challenged with 1% OVA 
aerosol for 20 min using DeVilbiss ultrasonic nebulizer (Sunrise Medical 
Respiratory Products, Somerset, PA) (Figure 7). Aerosol particle size is in 0.5 
to 5 μm range. Control mice were sensitized and challenged with saline.  
In the pharmacoproteomic study, dexamethasone phosphate (Sigma) was 
dissolved in sterile saline and was given intratracheally at 1 or 5 mg/kg 2 
hours before each OVA aerosol challenge on days 18, 19, and 20. Mice were 
placed into the clear mouse box in the V700000 CDS 2000 anesthesia 
machine (Surgivet, Waukesha, WI, USA) which will be ventilated with oxygen 
and isoflurane anesthetic. Intratracheal administration of 100 μl of drug 
solution was given to mice when they are under anesthesia. Control mice will 
be given saline intraperitoneal injection and saline aerosol challenge. The 
mice were sacrificed by cervical dislocation 24 hours after the last challenge. 
 
2.1.2 Chronic asthma model 
Male BALB/c mice 6-8 wk of age were sensitized by intraperitoneal injections 
of 20 µg OVA (Sigma) together with 4 mg Al(OH)3 in 0.1 ml phosphate-
buffered saline (PBS) on days 0 and 14. From day 18, animals were 




















Figure 7. Aerosol delivery system. Aerosol particle size is generated by the 
DeVilbiss ultrasonic nebulizer (Sunrise Medical Respiratory Products, 
Somerset, PA) in 0.5 to 5 μm size range. Up to 4 mice can be put into the 








0.5% OVA aerosol for 30 min/day on 3 days per week for 8 weeks. Control 
group was also sensitized the same way with OVA but challenged with same 
volume of sterile PBS for the same period. The mice were sacrificed 24 hours 
by cervical dislocation after the last challenge. 
 
2.2. Measurement of airway responsiveness 
Airway responsiveness to inhaled methacholine was measured in conscious 
and free-moving mice using a whole body plethysmograph (WBP) (Buxco, 
Charon, CT) (Figure 8) 24 hours after the last aerosol challenge as described 
previously (Duan et al., 2003). In chronic asthma model, airway 
hyperresponsiveness to inhaled methacholine were measured at 2-, 4-, 6-, 
and 8-week challenge time point. In brief, after 5 min of rest, mice were 
exposed to PBS and incremental doses of nebulized methacholine (5, 10, 20, 
40, and 80 mg/ml) subsequently. Each exposure consisted of a challenge 
period lasting 3 min followed by a break period lasting 5 min. The parameter 
Penh (enhanced pause) values were recorded every minute. Penh is a 
dimensionless value that characterizes the expiratory shape change and was 
defined as Penh = (Te/Tr-1)(PEF/PIF)(Figure 9) (Hamelmann et al., 1997). It 
consists of two ratios: one compares the duration of the early expiration to the 
duration of the late expiration; the other one compares the level of the peak 
expiratory flow to the level of the peak inspiratory flow. The highest Penh 
value obtained during each exposure was selected to represent the maximal 
response of this exposure. The highest value obtained in PBS exposure was 
regarded as the basal Penh value and other values were expressed as 


















Figure 8. The Buxco system consists of (a) BioSystem XA for Windows 
software, (b) MAXII preamplifier unit, (c) whole body unrestrained 
plethysmograph, (d) bias flow regulator, (e) aerosol controller, (f) aerosol 



























Figure 9. Computation of the airway responsiveness measured by whole 
body plethysmography. TI = inspiratory time (s), time from start of inspiration 
to end of inspiration; TE = expiratory time (s), time from end of inspiration to 
start of next inspiration; PIP = peak inspiratory pressure (ml/s), maximal 
negative box pressure occurring in one breath; PEP = peak expiratory 
pressure (ml/ s), maximal positive box pressure occurring in one breath; f = 
frequency (breaths/min), respiratory rate; Tr = relaxation time (s), time of the 











2.3. Immunoglobulin E measurement in serum 
The blood was collected by cardiopuncture 24 hours after the last challenge. 
In chronic model, blood was also collected at 2-, 4-, 6-, and 8-week challenge 
time point from tail veins. Blood samples were allowed to clot by leaving them 
undisturbed at room temperature for 30 minutes. The clot was removed by 
centrifugation at 2,000 x g for 10 minutes in a refrigerated centrifuge. 
Following centrifugation, serum was transferred into a clean tube, aliquoted 
and stored at -80°C until analysis. Total serum IgE and OVA-specific IgE 
levels were measured with an enzyme-linked immunosorbent assay (ELISA) 
using OptEIATM Set Mouse IgE kit (BD Biosciences, San Diego, CA, USA). 
Briefly, OVA or anti-IgE was coated overnight at 4°C. The plate was blocked 
with PBS (10% FBS, pH 7.0), and incubated for 1 hour at room temperature. 
The standards and sample were added into each well and incubated for 2 h. 
Detection biotinylated antibody and avidin-conjugated horseradish peroxidase 
(HRP) was added and incubated for 1 hour and then the substrate solution 
was added and incubated for 30 min in the dark. After adding stopping 
solution (1.8 N H2SO4), the plate was read at 450 nm within 30 min with 
wavelength correction at 570 nm in a Tecan RainBow plate reader (Tecan US 
Inc, Durham, NC, USA). Total serum IgE was determined using purified IgE 
(BD Biosciences), as standard and was expressed as ng/ml, while OVA-IgE 
level was expressed as OD value.  
 
2.4. Histology  
Twenty-four hours after the last OVA challenge, lung tissues were collected 
and fixed in 10% neutral formalin for 3-5 days, and subsequently processed in 
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Leica Tp1020 tissue processor (Leica Microsystems, Nussloch, Germany) and 
embedded in paraffin wax. The sequential procedure of procession was as 
below: 10% formalin x 3h, 70% ethanol x 1h, 80% ethanol x 1h, 90% ethanol 
x 1h, 100% ethanol x 1h, 100% ethanol x 1h, 100% ethanol x 1h, xylene x 
3.5h, xylene x 3.5h, xylene x 3.5h, molten wax x 1.5h, and molten wax x 1.5h. 
The embedded specimens were then cut into 5 μm sections, fixed upon the 
slides, and stained with Haematoxylin & Eosin (H&E), Periodic Acid-Schiff 
(PAS), or Masson Trichrome (all reagents were from Sigma). Briefly, slides 
were deparaffinized with HistoClear (National Diagnostics, Atlanta, GA, USA) 
and rehydrated by sequential passage through 100% ethanol, 90% ethanol, 
70% ethanol, and distilled water. The sections were then stained using 
different staining protocols: for H&E staining, in Harris Haematoxylin for 5 min, 
then differentiation in 0.1% acid alcohol for 30 sec followed by counterstaining 
in Eosin for1 min; for PAS staining, in Periodic Acid solution for 5 min, then in 
Schiff’s reagent for 15 min followed by counterstaining in Gill 3 Haematoxylin 
for 90 sec; for Masson Trichrome staining, in preheated Bouin’s solution at 
56°C for 15 min, then sequential staining in Weigert’s Haematoxylin for 5 min 
and in Fucshin solution for 5 min, and then rinsing in 1% Acetic acid for 5 min 
followed by staining in Aniline Blue for 5 min. Slides were then dehydrated by 
sequential passage through 70% ethanol, 90% ethanol, 100% ethanol, and 
finally cleaned with HistoClear. Once dry, the slides were mounted with 
HistoMount (National Diagnostics). 
 
2.5. Immunohistochemistry 
The detection of fibronectin was performed as previously described (Palmans 
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et al., 2000). Slides were incubated in 3% H2O2 in methanol for 10 min to 
block endogenous peroxidase activity after deparaffinization and rehydration. 
Then the sections were incubated in 0.4% pepsin solution (Sigma) in 0.01 N 
HCl at 37°C for 15 min. After blocking with serum, the sections were 
incubated with rabbit anti-mouse fibronectin antibody (US Biological, 
Swampscott, MA) at a dilution of 1:40 for 30 min. Immunoreactivity was 
detected by sequential incubations with a biotinylated secondary Ab, 
VECTASTAIN Rabbit Elite ABC kit (Vector Laboratories, Burlingame, CA), 
followed by 3, 3’-diaminobenzidine (DAB). The sections were counterstained 
with Haematoxylin for 30 sec. Slides were then dehydrated by sequential 
passage through 70% ethanol, 90% ethanol, 100% ethanol, and finally 
cleaned with HistoClear. Once dry, the slides were mounted with HistoMount 
(National Diagnostics). 
  
2.6. Quantitative analysis of the airways 
All slides were examined in a random blinded fashion. Evaluation of 
hyperplasia of goblet cells and degree of peribronchial and perivascular 
inflammation was based on a 5-point scoring system (Duan et al., 2004). 
Briefly, the scoring system for goblet cell was: 0, no goblet cells; 1, <25% of 
the epithelium; 2, 25–50%; 3, 50–75%; 4, >75%; the scoring system for 
inflammation was: 0, no cells; 1, occasional cell cluster; 2, a ring of cells 1 cell 
layer deep; 3, a ring of cells 2–4 cells deep; 4, a ring of cells >4 cells deep. 
Scoring was performed in 5-10 different fields for each lung section. Masson 
Trichrome stain and immunohistochemical stain analysis used Image-Pro Plus 
software (Media Cybernetics, Silver Spring, MD) as described (Cho et al., 
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2004). Briefly, nucleus in the lamina propria (defined as the region between 
the epithelial basement membrane and the smooth muscle layer) and in the 
whole epithelial layer were counted in the field and the length of the epithelial 
basement membrane was measured. The data were used to calculate the 
mean number of cells per 100 μm of epithelial basement membrane in the 
lamina propria and epithelia (Temelkovski et al., 1998). Five bronchioles in 
each slide were counted. The peribronchial Masson Trichrome staining and 
fibronectin staining were expressed as the area of each staining per 
micrometer length of basement membrane of bronchioles with 150–200 μm in 
internal diameter. At least 5 bronchioles were counted in each slide. The 
smooth muscle layer thickness was assessed at four predetermined 
bronchiole sites (12, 3, 6, and 9 o’clock) in at least 5 bronchioles of similar 
size (200-300 μm internal diameter) on each slide. 
 
2.7. BAL fluid cell counts 
The mice were sacrificed 24 hours after the last challenge. Tracheotomy was 
performed, and then the lung was lavaged with two separated dosages of 0.6 
ml of PBS via an intratracheal 18G cannula fixed in place with a ligature using 
a syringe attached to the cannula. Cells were obtained by centrifugation (1000 
x g for 5min). The supernatant was stored in -80°C for future proteomic 
analysis. Red blood cells present in the cell pellet were lysed by adding 2ml of 
0.87% NH4Cl solution for 10 minutes at room temperature and then 
centrifuged again to remove the supernatant containing the lysed cells. The 
resulting pellet was then resuspended in 1 ml of RPMI-1640 (containing 1% 
BSA) and a total cell count was performed with a haemocytometer (10 μl BAL: 
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10 μl Trypan stain). Aliquots (105 cells/ 150 μl) of the lavage suspension were 
then centrifuged by a Shandon Cytospin 3 (Thermo Electron Corporation, 
Pittsburgh, PA) at 600 rpm for 10 min at room temperature. For cytological 
examination, cytospin preparations were prepared, fixed, and stained in a 
modified Wright stain (Duan et al., 2003). Differential cell count was then 
performed on at least 500 cells (Figure 10).  
 
2.8. Proteomics analysis 
The general workflow of proteomic analysis involves sample preparation, first-
dimensional separation, equilibration, second-dimensional separation, staining, 
imaging, image analysis, and protein identification (Figure 11).    
 
2.8.1. Sample collection and preparation  
BAL fluid samples were precipitated with trichloroacetic acid (TCA) (10% final 
concentration) in an ice bath for 20 min, and subsequently centrifuged at 3500 
rpm for 15 min at 4oC. The pellet was re-suspended in ice-cold acetone and 
centrifuged as described above. The pellet was air-dried for a few minutes, 
solubilized in the lysis buffer containing 8 M urea, 2 M thiourea, 4% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 0.8% 
Pharmalyte, 65 mM dithiothreitol (DTT), protease inhibitor cocktail, 5 μg/ml 
DNase I, 20 μg/ml RNase A for 30 min at 4°C. The lysate was centrifuged at 
20800 x g for 15 min. The supernatant was aliquoted and stored at -80°C until 
further use. Protein concentration was measured by a modified Bradford 
assay (Bradford, 1976). Briefly, a standard curve was made using bovine 
serum albumin (BSA) which was prepared in the same lysis buffer as the 
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protein samples to be assayed with concentrations of 0, 5/30, 8/30, 10/30, 
15/30, 20/30, 1 μg/ml. Pipet 30 μl of each standard and sample solution into a 
clear tube and then 1 ml of diluted dye reagent (Bio-Rad Laboratories, 
Hercules, CA, USA) (1 dye: 4 water) was added into the tube. The samples 
were incubated at room temperature for 5 min and then the absorbance was 
measure at 595 nm in a microplate reader (Tecan Sunrise, Salzburg, Austria).  
  Lung tissues were homogenized in the lysis buffer as mentioned above 
using Heidolph Diax 900 homogenizer (Heidolph Instrument, Schwabach, 
Germany) on ice and then leaved still for solubilization for 30 min at 4°C. The 
protein solution was centrifuged at 20800 x g for 15 min. The supernatant was 
aliquoted and stored at -80°C until further use. Protein concentration was also 




























Figure 10. Type of cells typically found in BAL fluid. A, macrophage; B, 
































Figure 11. Scheme of proteomics workflow and instruments. A, Reswelling 
tray for rehydration (Amersham Biosciences) B, IPGphor for first-dimensional 
electrophoresis (Amersham Biosciences) C, EttanTM DALTtwelve vertical 
system for second-dimensional electrophoresis (Amersham Biosciences) D, 
GS-800 imaging densitometer (Bio-Rad Laboratories) E, PDQUEST (Version 
7.2) software (Bio-Rad Laboratories) F, Proteomics Analyzer with TOF-TOFTM 
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2.8.2. Two-dimensional electrophoresis 
The first- dimensional electrophoresis used Immobiline DryStrip (180 mm, pH 
4-7 and pH 6-11) (Amersham Biosciences, San Francisco, CA, USA). For pH 
4-7, the strips were rehydrated for 12h in 350 μl of solution including 
rehydration solution with 8 M urea, 2% CHAPS, 0.5% IPG buffer, 0.0005% 
Bromophen blue and protein sample in a reswelling tray (Amersham 
Biosciences). For pH 6-11, the strips were only rehydrated in the rehydration 
solution which was modified to 7 M urea, 2 M thiourea, 4% CHAPS, 2.5% DTT, 
10% isopropanol, 5% glycerol, 2% IPG buffer pH6-11 according to Hoving and 
co-workers (2002). The protein sample was loaded to the anodic side just 
before electrophoresis. Equal protein loads (80 μg of BAL fluid protein, 120 μg 
of lung protein) were used for all normal sample loading gels. Paper-bridge 
loading method was used for high sample loading (>400 μg) of pH6-11 gels 
(Sabounchi-Schutt et al., 2000). High sample loading was applied when the 
preliminary analysis was finished and desired spots needed to be cut for MS 
analysis. The isoelectrofocusing (IEF) was performed with an IPGphor 
(Amersham Biosciences) at 20°C using the protocol listed in Table 4. 
 
Table 4. Running protocols for IEF 
 Running Voltage & duration  








































Step & Hold 
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The strips were then equilibrated for 15 min in 6 M urea, 30% glycerol, 2% 
Sodium dodecyl sulphate (SDS), 50 mM Tris-Cl (pH 8.8), 1% DTT followed by 
another 15 min equilibration in the same solution except that DTT was 
changed to 2.5% iodoacetamine. The single-percentage 12% acrylamide gels 
were prepared in EttanTM DALT Gel Caster (Amersham Biosciences). About 
50 ml of gel solution containing 0.375 M Tris-Cl (pH 8.8), 0.1% SDS, 12% 
acrylamide, 0.05% ammonium persulfate (APS), 0.0005% (v/v) 
tetramethylethylenediamine (TEMED) was used for one gel. For second 
dimensional separation, the equilibrated strips were transferred onto the top of 
acrylamide gels and sealed with 0.5% agarose Gel electrophoresis was 
carried out in an EttanTM DALTtwelve vertical system (Amersham 
Biosciences) at room temperature. The electrophoresis condition was set at 
2.5 W/per gel for 30 min followed by 10 W/per gel for about 4-5 h until the dye 
front was 5 mm from the bottom. The gels were fixed in solution containing 
40% (v/v) ethanol, and 10% (v/v) acetic acid for overnight.  
 
2.8.3. Silver staining 
Silver staining was performed according to the manufacturer’s instruction 
(Amersham Biosciences). The gel containers were placed on a shaker 
(Unimax 2010, Heidolph Instrument) at 30-40 rpm throughout the staining. 
After fixation, the gels were sensitized with 30% (v/v) ethanol, 5% (w/v) 
sodium thiosulfate, and 6.8% (w/v) sodium acetate for 30 min. After washing 
with distilled water at 3 times for 5 min/each time, the gels were incubated in 
0.25% (w/v) silver nitrate for 20 min. Then the gels were rinsed shortly with 
distilled water at 2 times for 1 min/each time and developed in 2.5% (w/v) 
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sodium carbonate and 0.015% (w/v) formaldehyde until the desired intensity 
of spots was achieved. Then the development was terminated with 1.46% 
(w/v) EDTA-Na2 x 2H2O. The gels were scanned using GS-800 calibrated 
imaging densitometer (Bio-Rad Laboratories) following washing with distilled 
water at 3 times for 5 min/each time. 
 
2.8.4. Image analysis 
The PDQUEST (Version 7.2) software (Bio-Rad Laboratories) was used to 
detect, quantify, and match spots. All spots were carefully reviewed by 
operator to add missing spots, remove redundant spots, and rectify 
mismatched spots. Every spot was given a quantity of OD (optical density) 
fitted by Gaussian model. Because of potential variation in protein loading, 
rehydration and staining time, therefore, the gel images were normalized by 
total quantity of all matched spots to get rid of the effects of these non-
expression-related variations. Thus the quantity was expressed as parts per 
million (PPM) of total OD of all valid spots. Only the spots which appeared in 
all the gels of the same treatment group were selected for further analysis.  
 
2.8.5. In-gel digestion and MS analysis 
Protein spots of interest were excised from the stained gels and digested with 
modified trypsin (Promega, Madison, WI, USA) according to the method 
described before (Shevchenko et al., 1996). In general, in-gel digestion was 
performed in an orderly sequence starting from destaining, dehydration, 
drying, digestion, to extraction. Samples were analyzed using 4700 
Proteomics Analyzer with TOF-TOFTM optics work station (Applied Biosystems, 
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Foster City, CA, USA). Both MS and MS/MS data were acquired with a 
Nd:YAG laser with 200 Hz repetition rate and up to 4000 shots were 
accumulated for each spectrum. MS/MS mode was operated with 2 keV 
collision energy, mass range 800-3500 Da. Peptide mass fingerprints (PMF) 
of the tryptic peptides from MALDI-TOF MS and MS/MS data on the 
representative spots, together with the isoelectric points and molecular 
weights, were used to search the National Center for Biotechnology 
Information (NCBI) protein database with the programs Mascot at 
http://www.matrixscience.com and MS-Fit at http://prospector.ucsf.edu. 
 
2.9. Western blotting 
Twenty μg of total protein lysate diluted in sample buffer (62.5 mM Tris-HCl 
(pH=6.8), 10% glycerol, 5% 2-mercaptoethanol, 2% SDS, and 0.0125% 
bromophenol blue) was resolved on SDS-PAGE. 9.8% gels were used for 
Surfactant protein D (SP-D) was resolved in a 9.8% homogenous SDS-PAG, 
and lungkine was resolved in a 15% homogenous SDS-PAG. Then the 
proteins were electrotransferred to polyvinylidene difluoride (PVDF) 
membrane using a semi-dry transblotter (ATTO Corp., Tokyo, Japan), and 
followed by blocking in 5% non-fat milk dissolved in Tween 20-Tris-buffered 
saline (TTBS) (1M Tris-HCl pH 7.5, 0.9% NaCl, 0.05% Tween 20) for 1.5 hour 
at room temperature. The membranes were incubated with primary antibodies 
against β-actin (1:5000), lungkine (1:1000)  (R&D Systems, Minneapolis, MN) 
or SP-D (Chemicon International, Temecula, CA) (1:1000) followed by alkaline 
phosphatase (AP)-conjugated secondary antibodies (1:1000) 
(DakoCytomation, Glostrup, Denmark). Proteins were visualized 
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colorimetrically by adding substrate NBT (nitroblue tetrazolium) and BCIP (5-
bromo-4-chloro-3-indoyl-phosphate) (Bia-Rad) in AP buffer (100 mM Tris-HCl 
pH 9.5; 100 mM NaCl; 50 mM MgCl2). The gels were scanned and images 
were analyzed by Quantity-One software (Bio-Rad).  
 
2.10. RT-PCR 
Total mRNA from BAL fluid cells using a RNA isolation kit (Ambion, Austin, TX) 
and from lung tissues using TRIzol (Life Technologies, Gaithersburg, MD) 
were extracted. First strand cDNA was synthesized from 1 μg RNA using oligo 
(dT) 15 primers and 10 U AMV reverse transcriptase. PCR was performed in 
a GeneAmp PCR system 2700 thermal cycler (Applied Biosystems). The 
primers used and the product size are listed in Table 5. PCR products were 
run in a 1.5% agarose gel, visualized under UV light and quantitated using 
Gel-Pro imaging software (Media Cybernetics). 
 
2.11. Chitinase activity assay 
Chitinase bioactivity in BAL fluid was assayed using a fluorescence method as 
described (Zhu et al., 2004). Briefly, 50 μl of non-precipitated BAL sample was 
incubated at 37°C with 50 μl substrate 4-methylumbelliferyl-β-D-N,N’-
diacetylchitobioside (Sigma) in citrate/ phosphate buffer (0.1 M/ 0.2 M, pH 5.2), 
at a concentration of 0.17 mM for 15 min. Then the reaction was stopped with 
1 ml of glycine/ NaOH buffer (0.3 M, pH 10.6). The fluorescent product 4-
methylumbelliferone was measured using a SpectraMax Gemini EM 
fluorimeter (Molecular Devices, Sunnyvale, CA) with excitation wavelength at 
350 nm and emission at 445 nm. A 4-methylumbelliferone (Sigma) standard 
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curve was generated to quantify the enzyme activity. 
 
2.12. Statistics 
Changes in optical intensities of all matched protein spots between groups 
(n=9) were subjected to ANOVA followed by two-tail Student’s t-test using 
SPSS software (Chicago, IL). Data were expressed as mean ± SEM. The 





































































































































































































































































































































































































































































































































3. PROTEOMIC ANALYSIS OF ACUTE AIRWAY 
















3.1.1. Acute mouse asthma model  
By the end of the 21-day acute mouse asthma model, mice were sacrificed. 
BAL fluid and blood was collected. Total cell count and eosinophil count were 
dramatically increased (p < 0.05) in BAL fluid from OVA-treated mice as 
compared to saline control mice. To a lesser extent, neutrophil, macrophage 
and lymphocyte counts were also increased in allergic airway inflammation 
(Figure 12A). Airway responsiveness, determined by Penh measurement 
(Hamelmann et al., 1997), to inhaled methacholine was markedly increased (p 
< 0.05) in OVA-challenged mice as compared to saline-challenged mice 
(Figure 12B).  Serum levels of total IgE and OVA-specific IgE were 
substantially elevated in allergic airway inflammation (Figure 12C and D). In 
addition, OVA aerosol challenge induced marked infiltration of inflammatory 
cells, especially eosinophils, into the lamina propria, perivascular and 
peribronchiolar areas as compared to saline control (Figure 12E, F and I). 
Furthermore, OVA-challenged mice, but not saline-challenged mice, 
developed marked goblet cell hyperplasia and mucus hypersecretion within 




























































































































































Figure 12. Development of a murine acute asthma model (A) BAL fluids were 
collected 24 h after the last saline or OVA aerosol challenge. Total and differential 
cell counts were performed. EOS, eosinophil; NEU, neutrophil; MAC, 
macrophage; LYM, lymphocyte. (B) Airway responsiveness of mice challenged 
with aerosolized saline or OVA for 3 consecutive days to increasing doses of 
inhaled methacholine was measured using a single-chamber whole-body 
plethysmograph. Serum levels of total IgE (C) and OVA-specific IgE (D) were 
analyzed using ELISA (saline, n=11; OVA, n=11). Histological examination of lung 
tissue eosinophilia (E and F) and mucus production (G and H) after the last 
challenge of saline aerosol (E and G) or OVA aerosol (F and H) was performed 
under a microscope at 400x magnification. Abundant cell infiltrates with high 
percentage of eosinophils were localized in the perivascular and peribronchiolar 
region of OVA-challenged mice. OVA-challenged mice also showed increased 
periodic acid-Schiff stain (PAS)-positive goblet cells. Quantitative analyses of 
inflammatory cell infiltration (I) and mucus production (J) in lung sections (n=4) 
were performed as described previously. Data are presented as means± 

















3.1.2. 2-DE and image analysis of BAL fluid 
BAL fluid samples were obtained at the time when functional studies were 
performed. Samples from control mice (n=9) and OVA-sensitized and 
challenged mice (n=9) were resolved by 1-D electrophoresis on IPG gel strips 
in pH 4-7 range, followed by 2-D electrophoresis on homogeneous 12% SDS-
PAGE. Identical protein patterns were observed on 2-D gels of both control 
group and OVA group BAL fluids (Figure 13). Following image analysis, about 
500 spots were consistently detected and matched on all 9 separate gels of 
each treatment group (saline vs. OVA), and were selected for differential 
protein expression analysis based on a criterion of at least 3-fold change in 
optical density. At least 70%-80% of 500 spots were automatched by the 
software and left spots were manually matched due to slightly alteration of 
locations. A total of 28 protein spots were significantly altered (p< 0.05) in 
airway inflammation, and were subjected to peptide mass fingerprinting by 
MALDI-TOF MS. A representive searching result for spot 12 (SSP 8608) 
which is gob-5 protein was shown (Figure 14). Twenty-four spots were 
identified by MS and summarized in Table 6. The optical densities expressed 
as mean ± SEM and the location of the identified protein spots were shown in 
a master image (Figure 15). Graphical representation of these 24 identified 
proteins whose levels changed in asthmatic mice compared with control mice 
were showed as individual densities (Figure 16). A typical MALDI and MS/MS 
spectrum is also shown (Figure 17).Several proteins existed in multiple spots 
of similar molecular weights but of different isoelectric points, which may be a 
result of post-translational modifications such as glycosylation or 
phosphorylation (Graves and Haystead, 2002). We observed a marked 
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increase (p < 0.05) in some pro-inflammatory proteins in BAL fluid from 
allergic airway such as lungkine, a recently described chemokine (Rossi et al., 
1999), gob-5 (Nakanishi et al., 2001), and a family of chitinases including Ym1, 
Ym2 and acidic mammalian chitinase (AMCase) (Webb et al., 2001; Zhu et al., 
2004). We also detected a significant increase (p <0.05) in SP-D which may 
afford protective action against airway inflammation (Crouch and Wright, 
2001). On the other hand, the levels of some anti-inflammatory proteins such 
as haptoglobin (Yang et al., 2000) and α-1-antitrypsin (Eden et al., 1997) were 
































Figure 13. Representative 2-D gels of BAL fluid in acute asthma model samples 
corresponding to saline control (left panel) and OVA-treated (right panel). BAL 
fluids were separated by 2-DE using IPG at pH 4-7 and 12% SDS-PAGE. 






















































































Figure 14. A representive searching result (part) for spot 12 (SSP 8608) 




Table 6. Proteins identified with significant expression level changes in BAL 
fluid from asthmatic mice.   
 






Fold No. of 
peptide 




49% 295 5.7 12 
2 2330 Ym1 gi|285015 31% 120 42.5 11 
3 3218 Ym1 gi|285015 39% 242 58 15 
4 3227 Ym1 gi|285015 45% 109 16 15 
5 3307 Ym1 gi|285015 29% 78 7.4 11 
6 4207 Ym1 gi|285015 53% 121 4.2 19 
7 4221 Ym1 gi|285015 53% 110 10.5 16 
8 6203 Ym2 gi|2212390
7 
46% 95 71.4 15 
9 3004 Lungkine gi|5031129 35% 137 10 11 
10 4010 Lungkine gi|5031129 36% 128 7.2 10 
11 6011 Lungkine gi|5031129 34% 130 8.1 9 
12 8608 gob-5 protein gi|7513665 22% 102 140 14 
13 8630 gob-5 protein gi|7513665 27% 156 109 24 
14 2703 Polymeric 
immunoglobulin 
receptor 
gi|2804246 31% 149 4.9 25 
15 5020 Alpha-1-antitrypsin gi|90278 22% 78 -6 6 
16 5312 Surfactant protein D gi|6524992 37% 108 40 12 
17 6211 Surfactant protein D gi|6524992 35% 260 57.8 18 
18 7209 Surfactant protein D gi|6524992 32% 318 39 16 
19 8208 Surfactant Protein D gi|6524992 38% 81 19.7 11 
20 3220 Haptoglobin gi|8850219 34% 371 -4.6 19 
21 3430 Vitamin D-binding 
protein precursor 
(DBP) 
gi|111243 47% 280 -9 22 
22 3204 γ-Actin gi|809561 37% 355 8 18 
23 7123 Immunoglobulin light 
chain variable region 
(Fragment) 
gi|799373 27% 145 4.5 4 
24 3012 PEST phosphatase 
interacting protein 
gi|1857712 18% 80 20.5 12 
 
 
* Score is -10 x Log (P), where P is the probability that the observed match is a 
random event. Protein score of greater than 75 is considered significant (p <0.05).  
** Coverage refers to peptide sequence homology of at least 20% to the matched 
protein    
# SSP is spot number given by software according the pI and MW. 
Fold means fold changes in OVA-mice compared with control mice.  






















Figure 15. Differential BAL fluid protein expression profile upon OVA 
sensitization and challenge. The 2-DE reference map is composed of dataset of 
18 gels (n=9 for saline control and n=9 for OVA). The proteins were separated by 
2-DE using IPG at pH 4-7. The boxed proteins were identified by peptide mass 
mapping by MALDI-TOF MS. The numbers represent the spot identification 
numbers listed in Table 5. Spot optical densities were expressed as mean ± SEM. 
The optical densities of saline control and OVA-treated group were compared 


























Figure 16. Graphical representation of the 24 identified proteins whose levels 
changed in asthmatic mice compared to control mice. The columns from left to 
right in each graph are densities of 9 control samples (blue column) and 9 
asthmatic samples (red column). The digit beside the columns is the greatest 








Figure 17. A representative MALDI-TOF-TOF MS spectrum and subsequently 
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3.1.3. Immunoblotting and RT-PCR 
To verify the 2-DE findings, we conducted immunoblotting analyses and RT-
PCR on selected protein targets. As shown in Figure 18, the optical density of 
protein spots in 2-DE were highly reproducible. Western blot analysis of BAL 
fluids revealed significant increases (p < 0.05) in lungkine and SP-D protein 
levels in allergic airway inflammation. Equal loadings of BAL fluid proteins 
were confirmed using β-actin as internal control (data not shown). We also 
noticed that lungkine mRNA expression was absent from BAL fluid cells which 
comprise mainly of inflammatory cells like macrophage, eosinophil, neutrophil 
and lymphocyte, but was strongly induced in lung tissues (Figure 18), 
indicating that the source of lungkine is primarily from local lung 
microenvironment such the bronchoepithelial cells. On the other hands, 2-DE 
of BAL fluid and RT-PCR analysis of BAL fluid cells and lung tissues 
demonstrated increased gene and protein expressions of Ym1, Ym2, AMCase 
and gob-5 (Figure 18) in airway inflammation. The rank order for the basal 
expression levels of the 3 chitinases identified was Ym1 >> AMCase >Ym2. In 
fact, Ym2 level was undetectable in control BAL fluid. Upon OVA challenge, all 
3 chitinase levels were markedly elevated. In addition, basal gob-5 protein 
level in BAL fluid and mRNA level in BAL fluid cells were undetectable. Upon 




























Figure 18. Western blot analysis of BAL fluids using monoclonal antibodies 
targeted at lungkine (A) and SP-D (B). Top panels indicate the locations and 
protein spots of lungkine and SP-D in 3 randomly selected 2-D gels of control 
BAL fluid and allergic airway BAL fluid. The middle panels show Western blot 
results of three control and three allergic airway BAL fluids. Proteins (20 μg/lane) 
were separated by SDS-PAGE and probed with anti-lungkine and anti-SP-D 
antibodies. The blot was developed by NBT/BCIP, and analyzed using Gel-Pro 
imaging software. The bottom panels show the semi-quantitative data (means ± 
SEM, n=3) of target protein band intensities between control group and OVA-
treated group. Lungkine level was increased by 6.3-fold and SP-D level was 
increased by 3.0-fold in allergic airway inflammation. *Significant difference from 
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Figure 19. RT-PCR analysis of BAL fluid cells and lung tissues from control and 
OVA-treated mice targeting at gene expression of proteins that were found to 
have significantly altered expression levels in allergic airway inflammation by 2-
DE. Total mRNA from BAL fluid cells and lung tissues were extracted using a 
RNA isolation kit and the PCR products were separated in a 1.5% agarose gel 
and visualized under UV light. The experiments were repeated for four times with 
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3.2. Discussion 
The present study using 2-DE followed by MS-based protein analysis was able 
to identify major alterations in the expression levels of a number of proteins in 
BAL fluid collected from OVA-treated mice. During the course of this study, 
there were 2 separate reports published on the proteomics of allergic airway 
inflammation (Signor et al., 2004; Fajardo et al., 2004). However, their findings 
are quite different from each other and are also dissimilar to our observations 
in this study. In Fajardo’s report (2004), C57BL/6 mice were sensitized with 
OVA on days 0 and 14 but challenged with 200 µg OVA on days 30, 33, and 
35. In line with our study, they also identified Ym1 and Ym2 but surprisingly 
without AMCase. The absence of AMCase may be due to technical missing or 
the availability of AMCase gene information at the time of their study. In 
Signor’s study N rats were sensitized with OVA subcutaneously on days 1, 15 
and 22, and challenged with 0.3 mg/kg of OVA Intratracheally on day 29. They 
have identified some proteins which were also identified in our study including 
surfactant proteins, α-1-antitrypsin and haptoglobin. The differences in animal 
species and experiment protocols may be the main cause leading to different 
findings. Nevertheless, some extent of accordance can be observed given that 
some proteins were identified by different groups. The advantages of our study 
are that we used an established murine model of asthma (Duan et al., 2004) 
and had large sample size (n=9 for control and n=9 for OVA) for BAL fluid 
protein analysis to preclude false positive findings. Our present study reveals 
for the first time using proteomics analysis of BAL fluid major alterations in 
expression level of a newly described chemokine, lungkine, a family of 
chitinases, gob-5, SP-D, and other proteins in allergic airway inflammation. 
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Lungkine is a member of ELR-CXC chemokine family (Rossi et al. 1999; Chen 
et al., 2001). The CXC chemokine is characterized by the invariant four cysteine 
residues at the N terminus with the first two cysteines separated by a 
nonconserved amino acid. It is further classified by the presence or absence of 
the tripeptide motif glutamic acid-leucine-arginine (ELR) immediately preceding 
the CXC sequence (Olson et al., 2002). Lungkine, designated as CXCL15, has 
been shown to distribute exclusively in lung, especially bronchoepithelial cells, 
and be released into the airways. The expression of lungkine has previously 
been shown to be up-regulated by lipopolysaccharide, N.brasiliensis worms, 
aspergillus, and OVA sensitization and challenge (Rossi et al., 1999).  
Our 2-DE findings clearly showed a dramatic increase in BAL fluid lungkine 
level in allergic airway inflammation. The observation was further confirmed with 
immunoblotting and RT-PCR analyses. Lungkine has been shown to regulate 
neutrophil migration in the lungs (Rossi et al., 1999; Chen et al., 2001). The 
present study also showed a slight but significant increase in neutrophil level in 
BAL fluid obtained from asthmatic mice. The contributory role of neutrophils to 
the pathogenesis of allergic airway inflammation has not been firmly established. 
Nevertheless, cumulative evidence shows an allergen-specific early neutrophil 
infiltration after allergen challenge in mouse asthma model (Taube et al., 2003). 
During asthma exacerbation, a marked increase in neutrophils in sputum has 
been demonstrated (Fahy et al., 1995). Additional studies on the role of lungkine 
in the chemoattraction of other inflammatory cells and in asthma development 
are warranted. 
A family of chitinase proteins was found to be up-regulated in BAL fluid in 
allergic airway inflammation. In contrast to results reported by Webb et al. (2001) 
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showing higher Ym2 level than Ym1 in the allergic murine lung, our 2-DE 
analysis revealed more abundant expression of Ym1 than Ym2 in BAL fluid. It 
has been shown that allergen-induced up-regulation of chitinases was dependent 
on CD4+ T cells and IL-4 or IL-13 signaling (Webb et al., 2001; Welch et al., 2002; 
Zhu et al., 2004). AMCase induction has also been observed in asthmatic 
subjects. The catalytic activity of AMCase in the BAL fluid was found to be 
enhanced in asthmatic mice. The contributory role of AMCase to allergic airway 
inflammation has recently been confirmed as anti-AMCase serum decreased 
eosinophil and lymphocyte infiltration, and airway hyperresponsivess in asthmatic 
mice (Zhu et al., 2004). The role of Ym1 and Ym2 in airway inflammation is still 
unclear. Ym1/Ym2 has been shown to be an eosinophil chemotactic factor 
capable of regulating eosinophil trafficking with a potency equivalent to RANTES 
but weaker than eotaxin (Webb et al., 2001; Chang et al., 2001). Ym1 is also able 
to induce T lymphocyte chemotaxis (Chang et al., 2001). Furthermore, Ym1 and 
Ym2 have been shown to bind specifically to glucosamine oligomers such as 
chitobiose, chitortriose and chitotetraose, and to heparin/heparan sulfate 
proteoglycans, and suggested to play a role in airway wall remodeling in allergic 
asthma (Webb et al., 2001; Owhashi et al., 2000). A recent study reported that 
intratracheal administration of an adenoviral vector that expressed ECF-L 
(identical to Ym1) antisense suppressed airway hyperresponsiveness and 
eosinophil infiltration in mouse model (Iwashita et al., 2006). These results 
indicate that Ym1 may play a critical role in allergic inflammation and bronchial 
asthma. Additional studies are required to determine if Ym1 and Ym2 are 
pathogenic molecules and/or biomarkers for asthma. 
The present study demonstrated for the first time that gob-5 protein can be 
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detected in BAL fluid. Gob-5 (alias mCLCA3), a member of the chloride channel, 
calcium activated (CLCA) family, plays a critical role in active export of chloride 
ions that leads to mucin secretion from airway epithelial cells such as goblet cells. 
The levels of gob-5 and its human counterpart hCLCA1 were undetectable in 
normal airway, but were strikingly increased in allergic airway (Nakanishi et al., 
2001; Gruber et al., 1998; Hoshino et al., 2002). Indeed, our findings showed a 
significant surge in gob-5 expression not only in BAL fluid cells and lung lysates, 
but also in BAL fluid in allergic airway. Expression of gob-5 or hCLCA1 in allergic 
airway has been associated with significant induction of MUC5AC, a gene 
responsible for goblet cell metaplasia and mucin production (Nakanishi et al., 
2001; Hoshino et al., 2002). Depletion of gob-5 protein using antisense 
oligonucleotide suppressed mucus production, inflammatory cell infiltration, and 
airway hyperresponsiveness in asthmatic mice (Nakanishi et al., 2001). In line 
with a recent histological study showing gob-5 protein being secreted with mucin 
granules from goblet cells (Leverkoehne and Gruber, 2002), we were able to 
identify gob-5 in BAL fluid using 2-DE. Therefore, the notion of using gob-5 as a 
biomarker in BAL fluid or induced sputum for asthma warrants further study. 
Our 2-DE analysis also identified a striking increase in SP-D protein in allergic 
airway inflammation. SP-D is a member of the collagenous calcium-dependent 
lectin (collectin) family that includes SPA. Pulmonary SP-D is mainly synthesized 
and secreted by airway epithelial cells and is involved in the modulation of 
immune response via its carbohydrate recognition domain that specifically binds 
glycoconjugates expressed on the surface of leukocytes such as alveolar 
macrophages, and inhaled allergens (Crouch and Wright, 2001). The role of SP-
D in asthma is now being actively studied and appears to have some protective 
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functions. Our present findings are consistent with two previous studies showing 
elevated BAL fluid level of SP-D in a rat model of asthma (Kasper et al., 2002) 
and in patients with bronchial asthma (Cheng et al., 2000). It has been shown 
that SP-D can bind to mite allergen (Dermatophagoides pteronyssinus, Der p) to 
prevent its interaction with allergen-specific IgE, leading to decreased histamine 
release from sensitized basophils (Wang et al., 1998). In a mouse allergic 
bronchopulmonary aspergillosis model, SP-D has been shown to lower blood 
eosinophilia, pulmonary infiltration, allergic specific IgE level and Th2 cytokine 
levels (Madan et al., 2001). A recent study showed addition of rSP-D significantly 
inhibited Th2 cell activation and IgE and chemokines productions after allergen 
challenge in a mouse model (Haczku et al., 2006). Therefore, the observed 
increase in SP-D BAL fluid level from allergic airway reflects a compensatory 
anti-inflammatory response to lung inflammation.  
Additional proteins were found to be up-regulated in BAL fluid from allergic 
airway including polymeric immunoglobulin receptor (pIgR), immunoglobulin γ 
light chain and γ-actin. PIgR is expressed on the basolateral surface of airway 
epithelial cells capable of binding and transporting polymeric IgA and IgM to the 
apical surface for mucosal immunity (Kim and Malik, 2003). The expression of 
pIgR on human airway epithelium was found to be up-regulated by IL-4 and IFN-γ 
(Ackermann et al., 1999). The level of pIgR in nasal lavage fluid has been shown 
to increase in subjects with acute sinusitis (Casado et al., 2004). γ-actin is one of 
six functional actin isoforms identified. While α-actin is predominantly expressed 
in muscle cells and involved in muscular contraction, both β-actin and γ-actin are 
ubiquitously expressed and function as critical cytoskeleton supporting various 
biological activities (Khaitlina, 2001). The up-regulation of γ-actin in BAL fluid may 
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be due to increased cellular lysis in allergic airway. The relationship between 
increased pIgR and γ-actin levels and asthma is unknown. 
A few more proteins were found to be significantly down-regulated in allergic 
airway inflammation. These include vitamin D-binding protein (DBP), haptoglobin 
and α-1-antitrypsin. DBP is primarily a serum protein but is also present in the 
fluid that lines alveolar epithelium (White and Cooke, 2000). DBP is an actin 
scavenger that effectively reduces excessive actin polymerization and its ensuing 
coagulopathy in response to tissue injury. It also enhances C5a-induced 
neutrophil chemotaxis and mediates macrophage activation and subsequent 
apoptosis (Gomme and Bertolini, 2004). Whether DBP is a pro- or anti-
inflammatory molecule in allergic airway remains to be answered. Haptoglobin is 
mainly produced by the liver but the lung has been identified as a major 
extrahepatic source of this protein (Yang et al., 2000). Cumulative evidence has 
pointed out that haptoglobin has modulatory effects on immune response 
(Langlois and Delanghe, 1996; Dobryszycka, 1997). In line with the observation 
that serum haptoglobin levels were significantly lowered in a substantial portion 
of patients with asthma and/or rhinitis (Piessens et al., 1984), we identified a 
significant drop in BAL fluid haptoglobin level in allergic airways. However, the 
precise role of haptoglobin in allergic airway inflammation is unknown. α-1-
Antitrypsin is a serine proteinase inhibitor which has been found in BAL fluid from 
normal subjects (Noel-Georis et al., 2002; Signor et al., 2004; Wattiez et al., 
2000). α-1-Antitrypsin plays a critical role in inhibiting neutrophil elastase in the 
airways and its deficiency can lead to severe pulmonary emphysema (Eden et al., 
1997). Studies showed that asthmatics with low levels of α-1-antitrypsin were 
prone to develop airway hyperresponsiveness and reduced lung function (Eden 
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et al., 1997; von Ehrenstein et al., 2004). Vignola et al. (Vignola et al., 20031) 
suggested that elastase/α1-antitrypsin imbalance may be important in the 
development of airway remodelling. Consistent with those studies, we found a 
major drop in α-1-antitrypsin in both BAL fluid and serum (data not shown). 
Whether α-1-antitrypsin can be a new biomarker for evaluating asthma 
progression requires further study.  
In conclusion, we have demonstrated for the first time using proteomics 
approach significant changes in the level of lungkine, a family of chitinases, gob-
5 and SP-D in BAL fluid from OVA-treated mice. AMCase and gob-5 have been 
linked to the pathogenesis of asthma; whereas, the roles of lungkine, SP-D, Ym1 
and Ym2 in allergic airway inflammation require further studies. In addition to 
being considered as therapeutic targets, these proteins can also be developed as 






















4. PROTEOMICS OF AIRWAY INFLAMMATION AND 

















4.1.1. Serum IgE level and airway responsiveness 
Serum OVA-specific IgE levels were measured at different time points when 
mice were challenged with aerosolized OVA for 2, 4, 6, and 8 weeks. The 
OVA-specific IgE level was substantially increased after a 2-week challenge. 
However, the OVA-induced elevation of IgE levels gradually declined over a 
period of 8-week of OVA aerosol challenge. Nevertheless, by the end of 8-
week challenge, the OVA-specific IgE levels remained significantly higher than 
control mice (Figure 20). On the other hand, Figure 21 shows a gradual 
decline in airway hyperresponsiveness to increasing concentrations of 
methacholine in OVA-sensitized mice with prolonged OVA aerosol challenge 
from 2 to 8 weeks. Airway responsiveness, determined by Penh measurement 
(Hamelmann et al., 1997), was markedly increased (p < 0.05) at 2-week OVA 
aerosol challenge (Figure 20). After challenge for 8 weeks, only the highest 
dose (80 mg/ml) of methacholine induced an airway response with statistical 






















Figure 20. Serum levels of OVA-specific IgE were measured using ELISA 
(n=15 for each group) after mice were challenged with aerosolized OVA for 2, 
4, 6, and 8 weeks. Data are expressed as mean of optic density (OD) ± SEM. 


















































Figure 21. Airway responsiveness was measured after mice were challenged 
with aerosolized PBS or OVA for 2, 4, 6, and 8 weeks using a single-chamber 
whole-body plethysmograph (Buxco Technologies, Charon, CT) where mice 
were exposed to increasing doses of inhaled methacholine (n=5 for each 
group). Values are expressed as the ratio to basal Penh value. *Significant 




















































































4.1.2. Airway inflammation and airway remodeling  
Chronic OVA aerosol challenge induced increased inflammatory cell infiltration 
in perivascular and peribronchial regions (Figure 22B). In contrast to acute 
asthma models, cell infiltration into lamina propria and epithelial layer could 
even be observed in this chronic asthma model (Figure 22D). On the other 
hand, marked increase in PAS-positive stained areas in the epithelia indicative 
of the hyperplasia/metaplasia of goblet cells was evident during chronic OVA 
aerosol challenge (Figure 23). The thickness of the peribronchial smooth 
muscle layer in OVA-mice was significantly greater than that in PBS-
challenged mice (15.7 μm ±1.3 versus 5.6 μm ± 0.5) (Figure 24). Finally, 
collagen deposition was also examined using Masson Trichrome staining. 
PBS-mice showed a thin layer of matrix in restricted peribronchiolar region; 
whereas, OVA-mice showed a dramatic increase in both the extent and 
intensity of collagen staining (Figure 25). Fibronectin is another important ECM 
protein which can mediate contraction of collagen (Palmans et al., 2000). 
Increased airway deposition of fibronectin was also observed in OVA-




























Figure 22. Histological examination of haematoxylin & eosin (H&E) staining for 
general airway inflammation (A, B) and intra-epithelia cell infiltration (C, D) in 
chronic experimental asthma from PBS challenged mice (A, C) and OVA 
challenged mice (B, D). Quantitation of (E) airway inflammation was 
expressed as cells in lamina propria and epithelial layer per 100 μm length of 
basement membrane of bronchioles with 150-200 μm in internal diameter. 















































Figure 23. Histological examination of periodic acid-Schiff (PAS) staining for 
goblet cell hyperplasia/metaplasia in chronic model from PBS challenged mice 
(A) and OVA challenged mice (B). Quantitation of (C) mucus production was 
performed as described. n=5-8 for each group *Significant difference from 
















































Figure 24. Histological examination of smooth muscle thickness (arrow) in 
chronic model from PBS challenged mice (A) and OVA challenged mice (B). 
Quantitation of (C) smooth muscle thickness was assessed at four 
predetermined bronchiole sites (12, 3, 6, and 9 o’clock) in at least 5 
bronchioles of similar size (200-300 µm internal diameter) on each slide. n=5-8 















































Figure 25. Histological examination of Masson Trichrome staining for 
subepithelial collagen deposition in chronic model from PBS challenged mice 
(A) and OVA challenged mice (B). Quantitation of (C) collagen deposition 
(green stained area) was expressed as the area of each staining per 
micrometer length of basement membrane of bronchioles with 150–200 µm in 
internal diameter. n=5-8 for each group *Significant difference from PBS 















































Figure 26. Immunohistochemistry staining for fibronectin (arrow) in chronic 
model from PBS challenged mice (A) and OVA challenged mice (B). 
Quantitation of (C) fibronectin (brown stained area) was expressed as the area 
of each staining per micrometer length of basement membrane of bronchioles 
with 150–200 µm in internal diameter. n=5-8 for each group *Significant 



































4.1.3. Two-dimensional electrophoresis analysis 
Lung tissue and BAL samples were obtained 24 h after the last OVA challenge. 
Lung samples were resolved in IPG gel strips in both pH 4-7 and pH 6-11 
ranges; whereas only pH 4-7 strips were used for separating BAL fluid 
samples due to limited protein amounts in the lavage fluid. About 200-300 μg 
of proteins can be extracted from each BAL fluid sample. Following image 
analysis, about 1000 spots in the pH 4-7 lung sample image, 600-700 spots in 
the pH 4-7 BAL fluid sample image, and 400-500 spots in the pH 6-11 lung 
sample image were consistently detected and matched on all 10 separate gels 
of each treatment group. The highly variable pattern beyond pH 8 made it 
difficult to match. Totally over 100 spots were selected for differential protein 
expression analysis based on a criterion of at least 2-fold change in optical 
density with statistical significance between PBS control and OVA-challenged 
mice (p<0.05). However, only 66 spots were successfully identified by MALDI-
TOF-TOF (Table 7A). Forty-six of them were identified from pH 4-7 gel for lung 
tissue, 7 from pH 6-11 gel for lung tissue, and 13 from pH 4-7 gel for BAL fluid 
(Figure 27, Table 7B, C). The failure of identifying the other spots was mainly 
attributed to their low abundances. We noticed that the spots with normalized 
density below 500 were difficult to be identified successfully. Among the 66 
proteins identified, 41 (62%) proteins were up-regulated and 25 (38%) proteins 
were down-regulated in OVA-mice compared with PBS-mice, in contrast to a 
previous study in which the majority of proteins (80-90%) were up-regulated in 
BAL fluid from asthmatic subjects (Wu et al., 2005). 12 different proteins from 
BAL fluid were identified in chronic model compared with 13 of different 
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proteins in acute model. Among them, AMCase, Ym2, Gob-5, lungkine and 
















































Table 7A. Proteins with significant expression level changes identified by MS 
classified by their Gene Ontology Annotation (GOA) functions. 
 
Protein name A/N* Score# Coverage$ Fold& No. Peptide 
Cytoskeleton and related proteins 
Lymphocyte cytosolic protein 
1(LCP-1, L-plastin) 
gi|31543113 858 57% 2.0 33 49 
Lymphocyte cytosolic protein 
1(LCP-1, L-plastin) 
gi|31543113 967 45% 2.2 34 48 
Actin related protein 2/3 
complex, subunit 5 
gi|37805157 84 52% 2.5 35 10 
Capping protein (actin filament) 
muscle Z-line, beta (CapZ) 
gi|6753262 159 31% 2.0 36 13 
Msn, moesin gi|28703650 168 23% 5.2 37 24 
Actin interacting protein 1 gi|6755995 234 43% -2.1 38 25 
Keratin 7  gi|14861854 197 30% 2.1 42 19 
Immune response 
Resistin like- alpha (FIZZ1) gi|54611371 84 35% 10 39 5 
Ym2 gi|22123907 394 42% 360 40 23 
Ym2 gi|22123907 665 45% 31.3 41 24 
Immunoglobulin kappa-chain 
variable region 
gi|554065 79 33% 3.7 45 3 
Immunoglobulin light chain 
variable region 
gi|799373 80 36% 2.3 46 6 
Ig kappa chain V-III region gi|37196720 151 58% 2.1 47 6 
Ig kappa chain V-III region gi|37196720 80 32% 2.5 48 4 
Ig kappa light chain variable 
region 
gi|620021 90 50% 2.5 50 6 
Immunoglobulin gamma-chain gi|440121 85 22% 16.2 51 9 
Igh-4 protein (immunoglobulin 
heavy chain 4) (IgG1) 
gi|23958196 120 20% 7.7 53 8 
AMCase gi|37999744 295 49% 2.4 54 14 
Ym2 gi|22123907 158 46% 71.5 55 18 
Surfactant protein D gi|6524992 215 37% 2.1 64 14 
Lungkine gi|5031129 128 36% 2.6 59 11 
Lungkine gi|5031129 130 34% 2.3 60 12 
BF, properdin  gi|3986764 435 45% -3.8 65 20 
Cellular metabolism 
Protein phosphatase 2, 
regulatory subunit A, isoform 
alpha,  PP2A 
gi|8394027 221 40% -2.0 5 31 
Serpinb6a protein (protease 
inhibitor 6) 
gi|34784412 216 29% 2.3 6 15 
Pyruvate carboxylase gi|6679237 126 20% -2.2 7 19 
Pyruvate carboxylase gi|6679237 155 21% -2.3 8 17 
Adenylate kinase 1 gi|10946936 257 51% 2.0 9 15 
Phosphohistidine phosphatase gi|58037409 80 50% 2.0 10 9 
Glutathione peroxidase 3 
precursor  
gi|1170039 194 36% 2.0 11 13 
Superoxide dismutase 1,  gi|45597447 469 44% -2.8 12 12 
Ubiquitin-conjugating enzyme 
E2N 
gi|18017605 80 33% -3.9 13 5 
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Table 7A–Continued 
Protein name A/N* Score# Coverage$ Fold& Noa Peptideb 
Carboxylesterase 3 gi|175124887 467 35% -2.0 14 35 
Carboxylesterase 3  gi|175124887 128 30% -2.3 15 25 
Proteasome 26S non-ATPase 
regulatory subunit 11  
gi|33585718  215 40% -2.0 16 24 
Proteasome subunit beta type 
9 precursor (LMP-2) 
gi|17380240 305 43% 2.1 17 17 
Apolipoprotein A-I gi|6753096 167 31% 2.8 20 13 
Ribosomal protein S12 gi|63741520 224 42% -2.0 23 9 
Vesicle amine transport protein 
1 
gi|55715891 203 42% -2.6 24 19 
Myotrophin gi|6679961 196 32% -3.1 25 6 
Ubiquitin-conjugating enzyme 
E2D 3 
gi|13384718 75 36% -2.1 52 4 
Acute phase protein 
S100 calcium binding protein 
A8 (Calgranulin A) 
gi|7305453   133 49% -4.5 31 8 
S100 calcium binding protein 
A9 (Calgranulin B) 
gi|6677837 242 41% -4.8 32 14 
S100 calcium binding protein 
A11 (Calizzarin) 
gi|21886811 140 57% -3.1 30 8 
Transthyretin (prealbumin) gi|56541070 263 39% -2.6 56 10 
Pregnancy zone protein (alpha-
2-macroglobulin) 
gi|85861184 490 43% -3.3 57 21 
Serum amyloid P-component gi|38174334 414 44% -2.9 58 15 
Extracellular matrix  
Procollagen, type VI, alpha 1 gi|6753484   178 23% 2.0 43 15 
Procollagen, type VI, alpha 1 gi|6753484   123 23& 2.2 44 12 
Signal transduction 
14-3-3 protein epsilon gi|31981925 394 66% -2.1 1 29 
14-3-3 protein zeta/delta  gi|76611326 77 25% -2.0 2 6 
14-3-3 protein gamma gi|3065929 149 20% -2.0 3 8 
14-3-3 protein beta gi|3065925 142 32% -2.3 4 13 
Transport  
Cytochrome c oxidase, subunit 
Va 
gi|6680986 219 28% -2.2 18 8 
Ubiquinol-cytochrome c 
reductase core protein 1 
gi|46593021 1020 46% 2.1 19 32 
Transferrin gi|20330802 147 24% 4.4 21 23 
Transferrin gi|20330802 219 33% 2.4 22 28 
Ferritin light chain 1 gi|6753914 734 50% 2.7 61 21 
Hemopexin  gi|23956086 218 39% 2.1 62 32 
Gob-5 protein gi|7513665 661 33% 3.3 49 25 
Gob-5 protein gi|7513665 115 28% 6.4 66 14 
Calcium binding protein 
Calpain, small subunit 1 gi|6753256 624 35% 2.0 27 14 
Sorcin, Sri protein gi|13385076 385 40% 2.0 26 15 
Annexin A3 gi|7304887 745 52% 2.1 29 24 
Annexin A5 gi|1098603 513 71% 2.3 28 33 
Annexin A5 gi|1098603 430 42% 2.5 63 23 
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Table 7B. Proteins with significant expression level changes identified by MS 
classified by their locations and tissue sources.  
 
Proteins from lung (pH 4-7) 
No.  Protein name No. Protein name 
1 14-3-3 protein epsilon 24 vesicle amine transport protein 1 
2 14-3-3 protein zeta/delta  25 myotrophin 
3 14-3-3 protein gamma 26 Sorcin, Sri protein 
4 14-3-3 protein beta 27 calpain, small subunit 1 
5 protein phosphatase 2, regulatory 
subunit A, isoform alpha,  PP2A 
28 annexin A5 
6 Serpinb6a protein 29 annexin A3 
7 pyruvate carboxylase 30 S100 calcium binding protein A11 
8 pyruvate carboxylase 31 S100 calcium binding protein A8  
9 adenylate kinase 1 32 S100 calcium binding protein A9 
10 phosphohistidine phosphatase 33 lymphocyte cytosolic protein 1 
11 Glutathione peroxidase 3 precursor  34 lymphocyte cytosolic protein 1 
12 superoxide dismutase 1, soluble 35 Actin related protein 2/3 complex, 
subunit 5 
13 ubiquitin-conjugating enzyme E2N 36 capping protein (actin filament) 
muscle Z-line, beta 
14 Carboxylesterase 3 37 Msn, moesin 
15 Carboxylesterase 3  38 Actin interacting protein 1 
16 26S proteasome non-ATPase 
regulatory subunit 11 
39 Resistin like- alpha (FIZZ1) 
17 Proteasome subunit beta type 9 
precursor  
40 Ym2 
18 cytochrome c oxidase, subunit Va 41 Ym2 
19 ubiquinol-cytochrome c reductase core 
protein 1 
42 keratin 7  
20 apolipoprotein A-I 43 procollagen, type VI, alpha 1 
21 transferrin 44 procollagen, type VI, alpha 1 
22 transferrin 45 immunoglobulin kappa-chain 
variable region 
23 ribosomal protein S12 46 immunoglobulin light chain variable 
region 
 
Proteins from lung (pH 6-11) 
No.  Protein name No. Protein name 
47 Ig kappa chain V-III region 51 immunoglobulin gamma-chain 
48 Ig kappa chain V-III region 52 ubiquitin-conjugating enzyme E2D 3
49 gob-5 protein 53 Igh-4 protein 
50 Ig kappa light chain variable region   
 
Proteins from BALF (pH 4-7) 
No.  Protein name No. Protein name 
54 AMCase 61 ferritin light chain 1 
55 Ym2 62 Hemopexin  
56 Transthyretin 63 Annexin V 
57 pregnancy zone protein 64 Surfactant protein D 
58 Serum amyloid P-component 65 BF 
59 Lungkine 66 gob-5 protein 
60 Lungkine   
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Table 7C. Summary of proteins with significant expression level changes 
identified by MS classified. 
 
 pH 4-7 pH 6-11 Total
 Up-regulated Down-regulated Up-regulated Down-regulated  
Lung 25 21 6 1 53 
BALF 9 4   13 






Table 7D. Comparison of proteins identified in acute model and in chronic 
model.  





gob-5 protein  gob-5 protein 
Surfactant protein D  Surfactant protein D  
ferritin light chain 1 Alpha-1-antitrypsin 
pregnancy zone protein Polymeric immunoglobulin receptor 
Hemopexin Haptoglobin 
Annexin V Vitamin D-binding protein precursor (DBP)
BF γ-Actin 
Serum amyloid P-component Immunoglobulin light chain variable region 
(Fragment) 






* NCBI accession number 
# Score is -10 x Log (P), where P is the probability that the observed match is 
a random event. Protein score of greater than 75 is considered significant (p 
<0.05).  
$ Coverage refers to peptide sequence homology of at least 20% to the 
matched protein  
& up-regulated proteins in OVA-mice compared with control expressed as 
positive value (OVA/OS), down-regulation expressed as negative value 
(OS/OO) 
a The number assigned to the spot corresponding to the location in Figure 27. 
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Figure 27. Differentially expressed proteins in pH 4-7 gel for lung tissue (A), 
pH 6-11 gel for lung tissue (B), and pH 4-7 gel for BAL fluid sample (C) (n=10 
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4.1.4. Gene Ontology Classification 
Proteins identified were categorized according to the Gene Ontology 
Annotation (GOA) to define their cellular distribution and molecular function as 
well as biological processes. Cellular component is the part of a cell or 
extracellular environment of cells in which a gene product is a component. 
Molecular function is the action characteristic of a gene product. Biological 
process describes a phenomenon marked by changes that lead to a particular 
result, mediated by one or more gene products (please refer to 
http://www.ebi.ac.uk/GOA). From this database, 63.5% of M. musculus 
proteome have been assigned to the terms of molecular function, 54% to the 
terms of biological process, and 53.1% to the term of cellular component in 
GO system. In this study, all the differentially expressed proteins identified 
except Ym2 have assigned GO process terms. All 66 proteins were classified 
and summarized (Figure 28) to show the distribution of identified proteins 
using the GO indexing system. The protein complement covered a broad 
range of protein functional classes associated with diverse biological 
processes such as cytoskeleton, immune response, cell metabolism, signal 































Figure 28. Protein groupings of differentially expressed proteins in chronic 
mouse asthma model based on Gene Ontology Annotation. A, Cellular 
component is the part of a cell or extracellular environment of cells of which a 
gene product is a component. B, Molecular function is the action characteristic 
of a gene product. C, Biological process describes a phenomenon marked by 










































4.2. Discussion  
The application of proteomics to asthma research has not attracted much 
attention until last few years. Different animal models of acute asthma have 
been investigated using proteomics techniques. Houtman reported lung 
proteome alterations in a mouse model for nonallergic asthma in which 
BALB/c mice were sensitized with dinitro-fluorobenzene (DNFB) (Houtman et 
al., 2003). However, this study showed a totally different spectrum of proteins 
from what we have found which may be due to the different mechanisms 
underlying the development of atopic and nonatopic asthma. A group from 
Korean reported 15 proteins including Ym1, Ym2 that were differentially 
expressed in the lungs of BALB/c mice sensitized and challenged with OVA 
(Jeong et al., 2005). Interestingly Ym1 was also increased in the lung in their 
acute asthma model compared with that only Ym2 but not Ym1 was increased 
in the lung from chronic challenged mice in our study. That may suggests that 
Ym2 may be more related to airway remodeling progress. Fajardo and co-
workers (2004) reported a group of proteins in C57BL/6 mice which was 
increased after ovalbumin (OVA) sensitization and challenge. In line with our 
study, they also identified Ym1 in BALF and Ym2 in the lung from OVA-treated 
mice but failed to identify Ym2 in BALF. The major difference between these 
studies and our study is that the animal models in these studies were all acute 
asthma models in which only short time but high dose exposure to aerosolized 
antigen is involved. These acute animal models are now well recognized that 
they cannot successfully demonstrate airway structural alterations. Lack of 
cytoskeleton proteins identified in these previous studies also demonstrated 
the limitation of studying lung proteome alteration in acute asthma models.  
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In this study, a chronic mouse asthma model was developed and more than 
60 proteins were identified with significant differential expression levels as 
compared with control samples. 53 of 66 proteins were from the lung and 13 
proteins were from BALF. The number of proteins up-regulated was slightly 
higher than that of down-regulated proteins in OVA-mice (34: 25). For lung 
tissue, the ratio was 25:21, and for BALF the ratio was 9: 4. However, in our 
previous study in an acute asthma model, 21 of 24 proteins were up-regulated 
in OVA-mice. That contrast may indicate the difference in the pathogenesis 
between acute asthma model and chronic asthma model.    
The actin cytoskeleton plays an important role in cell morphology and 
motility. It has now become evident that dynamic rearrangements in the actin 
cytoskeleton play a central role for inflammatory cell functions, in particular 
with regard to their activation and migration. In this study, a group of 
cytoskeleton-related proteins, including Lymphocyte cytosolic protein 1 (LCP-1, 
L-plastin), actin related protein 2/3 complex (Arp2/3) and capping protein 
muscle Z-line (CapZ), were up-regulated at 2-2.5 fold in asthmatic mice as 
compared to control mice. L-plastin is a member of the plastin family which are 
actin-bundling proteins facilitating microspike and filopodia formation (Samstag 
et al., 2003). L-plastin is expressed exclusively in leukocytes and has been 
shown to be able to regulate neutrophil and T lymphocyte migration and 
activation (Chen et al., 2003b). A complex of seven proteins called Arp2/3 
complex is the best characterized cellular initiator of actin filament nucleation 
(Higgs and Pollard, 2001). Upon activation by promoting factors such as 
WASp/Scar family proteins, Arp2/3 complex will initiate actin polymerization. 
CapZ, an actin capping protein, binds the barbed ends of actin and stabilizes 
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the actin filament. Hence, CapZ can facilitate actin polymerization by forming 
nuclei for elongation of filaments (dos Remedios et al., 2003). In addition to 
anchoring actin, CapZ can bind protein kinase C (PKC) and promote PKC-
mediated control of myofilament activation and contractility (Pyle et al., 2002). 
In our study, CapZ level was increased in chronic mouse asthma and that may 
be a factor leading to increased airway stiffness. On the other hand, two 
regulators of cytoskeleton formation, such as Actin interacting protein 1 (AIP1) 
and protein phosphatase 2 (PP2A), were down-regulated in chronic asthma 
model. AIP1 can bind to both actin and cofilin as a cofactor. Cofilin binds to G- 
and F-actin and induces actin severing and depolymerization, working as an 
actin depolymerization augmentator (Fujibuchi et al., 2005). Therefore, down-
regulation of AIP1 may inhibit the activity of cofilin and thus enhance actin 
filament formation and stabilization. PP2A is a ubiquitous enzyme which has 
been shown to dephosphorylate cofilin and thereby activate cofilin (Ambach et 
al., 2000). The decrease of PP2A could also lead to enhanced actin formation. 
These cytoskeleton-related proteins form a network to regulate the formation 
and degradation of actin (Figure 29) and the regulation of this network in this 
study showed a new insight into the roles of cytoskeleton-related protein in 
development of chronic asthma.  
As a structural protein, moesin plays a role as a cellular stabilizer, linking the 
cellular actin cytoskeleton to the membrane and thus participating in the 
control of cell shape, adhesion, locomotion, and signaling (Iontcheva et al., 
2004). There is increasing evidence for the involvement of moesin as a key 
molecule in adhesion events during the inflammation process in different cell 
types such as macrophage and lymphocyte (Barreiro et al., 2002). Taken 
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together, chronic asthma may be associated with differential expression of 
certain cytoskeletons that may regulate inflammatory cell migration and airway 
remodeling. 
Keratin filaments constitute type I and type II intermediate filaments (IFs), 
with at least 20 subtypes. It has been reported that keratins are distributed in a 
tissue-specific manner and that immunohistochemistry of a certain keratin is 
useful for the determination of tissues of origin in several types of tumors (Chu 
and Weiss, 2002). The expression of keratin 7 is restricted to a subgroup of 
glandular epithelial origin. Keratin 7 can be a marker for the discriminating 
diagnosis of lung cancer (Ikeda et al., 2006). The up-regulation of keratin 7 
may indicate hyperplasia of epithelial glands in chronically inflamed airway. 
Collagen VI is one of major fibril-forming collagens. The increase of collagen 
VI has been observed in both asthma patients and experimental asthma 
(Palmans et al., 2002). However, we did not identify other types of collagens in 
our gels. In another study, collagen VI was also the only collagen type which 
was up-regulated by IL-13 in airway smooth muscle cells using proteomics 
(data not shown). The possible reasons could include higher abundance of 
collagen VI than other types (Kielty et al., 1991) and poor accessibility and 
resolution of high-molecular mass proteins in 12% acrylamide gels. The failure 
of identifying fibronectin in 2-d gels may also be attributed to its high molecular 




























Figure 29. Schematic diagram of the interactions between some actin binding 
proteins and actin filament. Actin nucleation (generation of new actin filaments) 
is initiated by binding of Wasp to the Arp2/3 complex. After dephosphorylated 
by PP2A, cofilin is activated and binds actin filament leading to break and 
depolymerization of actin filament. AIP1 binds to cofilin as a cofactor and 
facilitates the actin turnover. L-plastin bundles parallel actin filaments. CapZ 
binds the barbed end of the actin filament and terminates the actin 
polymerization and stabilizes the formed filament. 
 
In line with our findings in the acute mouse asthma, gob-5 level was 
dramatically increased in chronic mouse asthma. Gob-5 has been implicated 
for mucus overproduction in allergic airway inflammation as discussed in last 
chapter. Although a recent report using gob-5 knockout mice revealed that 
gob-5 is not essential for mucus overproduction in a mouse asthma model 
(Robichaud et al., 2005), more studies supported the indispensable role of 
gob-5 in goblet cell hyperplasia and mucus hypersecretion (Long et al., 2006). 
Studies also showed that gob-5 is a secreted non-integral membrane protein 
serving as a signal molecule rather than an ion channel (Gibson et al., 2005; 
Mundhenk et al., 2006), thus gob-5 is able to regulate cell infiltration in airway 








Another interesting finding is the dramatic up-regulation of a group of 
chitinase and FIZZ Family (ChaFF) proteins including Ym2, AMCase, and 
Fizz1. Fizz1, also called hypoxia-induced mitogenic factor (HIMF), was a 
newly found cytokine which has been shown to have mitogenic, angiogenic 
and antiapoptotic effects (Wagner et al., 2004) and to stimulate smooth muscle 
actin and collagen expression in fibroblasts (Liu et al., 2004). This is the first 
time to show up-regulation of Fizz1 in lung tissue from experimental chronic 
asthma model. AMCase has recently been shown by our laboratory to be up-
regulated in an acute mouse asthma model and its role in the pathogenesis of 
asthma was investigated by Zhu and co-workers (2004). Ym2 (chitinase 3 like-
4), similar to Ym1 (chitinase 3 like-3), has been suggested to play a role in 
airway wall thickening by its ability to recognize glycan or carbohydrate 
structures on cell surface and in extracellular matrix (Webb et al., 2001). Two 
homologues of Ym2 in human, GP-39 (chitinase 3 like-1) and YKL-39 
(chitinase 3 like-2) were also increased in BAL fluid after antigen challenge 
(Guttmacher and Collins, 2003). Unexpectedly, Ym1 level was not altered in 
chronic mouse asthma in contrast to that both Ym1 and Ym2 were elevated in 
acute asthma models (Jeong et al., 2005; Fajardo et al., 2004). Thus, AMCase, 
Ym2 and Fizz1 could be considered as biomarkers of airway remodeling and 
as potential therapeutic targets for asthma.  
The role of oxidative stress in the development of asthma has recently been 
extensively studied (Comhair et al., 2005b). Superoxide dismutase (SOD), a 
critical anti-oxidative enzyme, has been shown to play a role in AHR and 
airway remodeling (Comhair et al., 2005a, 2005b). SOD exists as three 
isoforms: the cellular form (SOD1, Cu/ZnSOD), the mitochondrial form (SOD2, 
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MnSOD), and the extracellular form (SOD3, EC-SOD). It is the reduction of 
SOD1 that has been correlated to airway epithelia apoptosis, airflow 
obstruction and AHR (Comhair et al., 2005a, 2005b). In fact, over-expression 
of SOD1 could decrease allergen-induced airway inflammation (Larsen et al., 
2000). Interestingly, the other two important anti-oxidative enzymes, 
glutathione peroxidase (GPx) and catalase, did not show any correlations with 
asthma development (Comhair et al., 2005a, 2005b; Clifton et al., 2005). In fact, 
we observed an increased level of glutathione peroxidase 3 as compared with 
a decreased level of SOD1 in chronic mouse asthma. Our findings also 
suggest that at least SOD1 and GP-3 may play different and non-redundant 
roles in oxidative process.  
A group of acute phase proteins (APPs) were identified in this study. APPs 
are a class of proteins that are synthetized mainly in the liver in response to 
inflammation (Petersen et al., 2004). They can be classified according to the 
magnitude of their increase (positive acute phase proteins such as haptoglobin, 
hemopexin, serum amyloid A/ P, and C-reactive protein or decrease (negative 
acute phase proteins such as albumin, transthyretin (prealbumin) and 
apolipoprotein A-I (ApoA-I)) in serum concentrations during an acute phase 
response. APPs have a wide range of activities that contribute to host defence: 
they can directly neutralize inflammatory agents, help to minimize the extent of 
local tissue damage, as well as participate in tissue repair and regeneration. In 
this study, we observed a surprising discrepancy in the alterations of APPs 
expression. Among positive APPs, a group of proteins related to ion 
metabolism including hemopexin and ferritin were found to be up-regulated; 
whereas, serum amyloid P-component, S100 calcium-binding proteins and 
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pregnancy zone protein (PZP) were down-regulated in chronic mouse asthma. 
Among negative APPs, ApoA-I and transferrin were increased, however, 
transthyretin was decreased. These findings may indicate the different 
responses of APPs in chronic inflammatory scenario. APP synthesis is under 
control by inflammatory mediators such as TNF-α, IL-1, IL-6, IL-11, IFN-γ and 
TGF-β (Petersen et al., 2004). The differential expression of APPs may be due 
to different cytokine profiles in chronic asthma. Understanding the roles of 
these proteins in asthma development requires further studies.  
A group of calcium binding proteins were up-regulated in OVA-treated mice 
which included calpain, sorcin, and annexin A3 and A5 proteins. Excessive 
activation of calpains has been implicated in the pathophysiology of 
inflammation, trauma, and ischemia reperfusion injury (Tissier et al., 2004). 
Inhibition of calpain activity could reduce acute and chronic inflammation in 
animal models which may be due to attenuation of leukocyte endothelium 
interactions by calpain inhibitor (Cuzzocrea et al., 2000; Tissier et al., 2004). 
Sorcin has been shown to regulate cardiac contractility and overexpression of 
sorcin can enhance cardiac contraction (Frank et al., 2005; Farrell et al., 2003). 
We speculate that increased sorcin level may contribute to airway obstruction 
in chronic asthma. Annexins belong to a class of Ca2-binding proteins 
characterized by the property of binding to negatively charged phospholipid 
membrane surface (Gerke et al., 2005). In humans, 12 annexin proteins 
(annexin A1–A11, annexin A13) have been identified, but the functions of 
annexins are not fully understood. Some annexins have been shown to be 
involved in membrane-cytoskeleton organization, promoting exocytosis, 
regulation of inflammation and apoptosis (Gerke et al., 2005). Annexin A3 has 
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been shown to promote granules aggregation in neutrophils (Le Cabec and 
Maridonneau-Parini, 1994) and to induce angiogenesis (Park et al., 2005), and 
annexin A5 shows anticoagulation effect (Gerke et al., 2005).  
We have also observed a consistent down-regulation of four isoforms (beta, 
gamma, epsilon, and zeta/delta) of 14-3-3 proteins in chronic mouse asthma. 
14-3-3 proteins have been shown to bind to more than 200 different proteins 
and regulate diverse cellular processes such as cell cycle, signaling 
transduction, and apoptosis (van Heusden, 2005). Inactivation of 14-3-3 
proteins has been shown to exacerbate cardiac hypertrophy and fibrosis in a 
recent report (Gurusamy et al., 2005). At this moment, there is no evidence to 
associate 14-3-3 proteins with asthma development directly, we speculate that 
down-regulation of these four isoforms of 14-3-3 protein may be linked to 
airway remodeling process such as smooth muscle and goblet cell 
hypertrophy, or subepithelial fibrosis. 
In this study, we identified over 100 spots which were significantly changed, 
but only half of them could be identified by MS due to low abundances. 
Therefore, in future using liquid chromatography combined with MS could be a 
meaningful complement in analyzing those low-abundance proteins and 
peptides (Crameri, 2005; Wu et al., 2005). In conclusion, this is the first report 
of proteomic analysis of airway remodeling in the chronic experimental asthma 
model. The identified proteins reflect the complexity of the pathophysiology of 
asthma. Some proteins are the first time linked to the development of asthma. 
This study provides new insight into the better understanding of the 













5. PHARMACOPROTEOMIC ANALYSIS OF 















5.1.1. Dexamethasone Inhibits Airway Inflammation in Mice  
BAL fluid was collected 24 hours after the last OVA aerosol challenge, and 
total and eosinophil counts were performed. OVA/OVA mice showed 
significantly (p < 0.05) higher total cell and eosinophil counts as compared 
with saline-sensitized and -challenged (saline/saline) and OVA-sensitized and 
saline-challenged (OVA/saline) control mice (Figure 30A). Dexamethasone (1 
and 5mg/kg) substantially reduced the total cell number and eosinophils 
recovered in BAL fluid as compared to OVA/OVA untreated control. Serum 
was collected 24 hours after the last OVA aerosol challenge. Level of OVA-
specific IgE was determined using ELISA. Substantial elevation in OVA-
specific IgE was observed in OVA/OVA mice as compared with saline/saline 
and OVA/saline controls (Figure 30B). Intratracheally given dexamethasone 
dose-dependently lowered OVA-specific IgE levels by about 20% and 50% (p 
< 0.05) at 1 and 5 mg/kg, respectively. Histological examination of mouse lung 
tissue reveals that OVA aerosol challenge induced marked infiltration of 
inflammatory cells, especially eosinophils, into lamina propria, perivascular 
and peribronchiolar areas as compared to saline aerosol challenge (Figure 
31A). Intratracheal dexamethasone (1 and 5mg/kg) dose-dependently 
attenuated eosinophil-rich leukocyte infiltration as compared with OVA/OVA 
untreated control (Figure 31A and E). On the other hand, OVA/OVA mice, but 
not OVA/saline mice, developed marked goblet cell hyperplasia and mucus 
hypersecretion within the bronchi in the lung (Figure 31B). The OVA-induced 
mucus secretion was significantly abated by dexamethasone as compared to 














Figure 30. Anti-inflammatory effects of dexamethasone on mouse allergic 
airway inflammation. (A) BAL fluids were collected 24 hours after the last 
saline or OVA aerosol challenge. Total (empty bar) and eosinophil (filled bar) 
counts were performed as described. (B) Serum level of OVA-specific IgE was 
analyzed using ELISA. SS (saline/saline, n = 4), OS (OVA/saline, n = 4), OO 
(OVA/OVA, n = 9), D1 (dexamethasone-treated, 1 mg/kg, n = 16), D5 
(dexamethasone-treated, 5mg/kg, n = 16). *Significant difference from OO 













































































































Figure 31. Histological examination of lung tissue cell infiltration (A) and 
mucus production (B) 24 hours after the last saline or OVA challenge was 
performed under a microscope at 400x magnification. Quantitative analyses of 
inflammatory cell infiltration (C, n = 4) and mucus production (D, n = 4) in lung 
sections were performed blinded as described. *Significant difference from 
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5.1.2. Dexamethasone Alters Mouse BAL Fluid Proteome  
BAL fluid samples were collected at the time when airway inflammation 
parameters were examined. Samples from saline/saline (n = 9), OVA/saline (n 
= 9). OVA/OVA (n = 9), OVA/OVA treated with dexamethasone 1 mg/kg (n = 9) 
and OVA/OVA treated with dexamethasone 5 mg/kg (n = 9) were resolved by 
2-DE. Similar protein patterns were observed on 2-DE of all groups studied 
(Figure 32). Following image analysis, about 500 spots were consistently 
detected and matched on all 9 separate gels of each group, and were 
subjected to differential protein expression analysis. A total of 26 BAL fluid 
protein species were significantly altered (p< 0.05) in mouse allergic airway 
inflammation with and without dexamethasone treatment, and were subjected 
to peptide mass fingerprinting by MALDI-TOF mass spectrometry. The 26 
spots were identified by mass spectrometry and summarized in Table 8. In line 
with our previous findings, allergic airway inflammation is associated with the 
up-regulation of proteins such as the family of chitinases (AMCase, Ym1 and 
Ym2), gob-5, lungkine, and surfactant protein-D (SP-D) and down-regulation 
of proteins such as vitamin D-binding protein (DBP) and α-1-antitrypsin. The 
location of identified protein spots were shown in a representative image 
(Figure 33) and the quantitative changes of optical intensities of the identified 
protein spots expressed as mean ± SEM were shown in Figure 34. AMCase, 
Ym1, Ym2, and gob-5 have been shown to be related to airway inflammation, 
hyperresponsiveness, and airway remodeling (Nakanishi et al., 2001; 
Donnelly and Barnes, 2004; Zhu et al., 2004); whereas, SP-D may have 
protective functions in the airways (Haczku et al., 2004). We have for the first 
















































Figure 32. Representative 2-D 
gels of BAL fluid samples 
corresponding to SS 
(saline/saline), OS (OVA/saline), 
OO (OVA/OVA), D1 
(dexamethasone 1 mg/kg), D5 




Table 8. Proteins with differential expression levels in BAL fluid from 
dexamethasone-treated mice.  
 





change   
No. 
peptide 
1 AMCase gi|37999744 -1.3 -6.8 15 
2 Ym1 gi|51315803 -2.9 -10.7 11 
3 Ym1 gi|51315803 -2.3 -11.2 13 
4 Ym1 gi|51315803 -1.1 -10.0 15 
5 Ym1 gi|51315803 -2.5 -3.3 11 
6 Ym1 gi|51315803 1.2 -2.7 17 
7 Ym1 gi|51315803 -1.2 -5.5 15 
8 Ym2 gi|22123907 -1.9 -12.8 24 
9 Lungkine gi|5031129 -2.2 -7.8 12 
10 Lungkine gi|5031129 -2.2 -4.0 14 
11 Lungkine gi|5031129 -2.5 -5.3 16 
12 gob-5 protein gi|7513665 -1.0 -5.8 14 
13 gob-5 protein gi|7513665 -1.2 -3.7 19 





15 Alpha-1-antitrypsin gi|90278 4.6 4.7 8 
16 Surfactant protein D gi|6524992 -2.0 -172.4 27 
17 Surfactant protein D gi|6524992 -1.5 -4.1 33 
18 Surfactant protein D gi|6524992 -1.7 -6.0 17 
19 Surfactant Protein D gi|6524992 -2.4 -4.0 21 
20 Haptoglobin gi|8850219 3.0 2.4 22 





22 γ-Actin gi|809561 -1.2 -2.2 20 
23 Immunoglobulin light chain 




24 Hemopexin  gi|23956086 -1.3 -2.3 15 
25 Hemopexin gi|23956086 -1.7 -2.9 16 
26 PEST phosphatase 




















































Figure 33. A representative gel image indicates the locations of all 26 BAL 
fluid protein spots that have been shown to be significantly altered by 
dexamethasone. Numbers correspond to the spot identification numbers listed 

























































































































































Figure 34. Histograms showing the optical intensities (OD) of identified 
protein spots among SS (saline/saline), OS (OVA/saline), OO (OVA/OVA), D1 
(dexamethasone, 1 mg/kg) and D5 (dexamethasone, 5mg/kg) groups. Spot 
optical densities (OD) were expressed as mean ± SEM. OD of OVA/OVA 
control and dexamethasone 1 and 5 mg/kg treatment groups were compared 
using ANOVA followed by Student’s t-test. *Significant difference form 






























BAL fluid levels of AMCase, Ym1, Ym2 and gob-5 in allergic airways. In 
addition, dexamethasone markedly suppressed BAL fluid levels of SP-D, 
lungkine, polymeric immunoglobulin receptor (pIgR) and PSTPIP (PEST 
domain-enriched protein tyrosine phosphatase) in airway inflammation. 
Equally novel findings are that dexamethasone reversed the down-regulation 
of DBP, haptoglobin and α-1-antitrypsin in allergic airway inflammation. 
 
5.1.3. Immunoblotting and RT-PCR 
To verify the 2-DE findings, we conducted immunoblotting and RT-PCR 
analyses on selected protein targets. Western blot analysis of BAL fluids using 
mAb targeted at SP-D and lungkine revealed significant increases (p < 0.05) 
in SP-D and lungkine levels in allergic airway inflammation, and significant 
decreases (p < 0.05) in SP-D and lungkine protein levels by dexamethasone 
at 1 and 5 mg/ kg (Figures 35A-C). Equal loadings of BAL fluid proteins were 
confirmed using β-actin as internal control. Upon OVA aerosol challenge, the 
mRNA levels of three chitinase members (AMCase, Ym1 and Ym2) were 
markedly elevated in lung tissues, which corroborate well with the protein up-
regulation observed in 2-DE. Likewise, dexamethasone also significantly 
blocked all three chitinase mRNA expressions in allergic airway inflammation. 
In contrast, chitotriosidase, another member of mammalian chitinases (Nio et 
al., 2004), was not affected by allergic airway inflammation nor by 
dexamethasone treatment. Consistent with 2-DE findings, the mRNA levels of 
gob-5 and its downstream molecule MUC5AC were enhanced in airway 
inflammation but were suppressed dose-dependently by dexamethasone. 

































Figure 35. Western blot analysis (A) of BAL fluids using mAbs targeted at 
lungkine (upper panel) and SP-D (lower panel). Proteins (10 μg/lane) were 
separated by SDS-PAGE. The blot was developed colorimetrically by 
NBT/BCIP and analyzed using Gel-Pro imaging software. Semi-quantitative 
analyses (B and C) (means ± SEM, n = 4) of target protein band intensities 
among SS (saline/saline), OS (OVA/saline), OO (OVA/OVA), D1 
(dexamethasone, 1 mg/kg) and D5 (dexamethasone, 5mg/kg) groups. 













































allergic airways and down-regulated by dexamethasone. Gene expression of 
TH2 cytokines IL-4 and IL-13 was strongly induced in allergic airways and 
was completely abolished by dexamethasone (Figure 36).     
 
5.1.4. Dexamethasone Partially Reduces BAL Fluid Chitinase Activity 
The chitinase bioactivity of BAL fluid from each group of mice was assayed. 
As compared with saline/saline and OVA/saline controls, OVA/OVA group 
demonstrated about 5-fold increase in BAL fluid chitinase activity. 
Intratracheal dexamethasone partially inhibited the chitinase activity in a dose-
dependent manner. At 5 mg/kg dexamethasone, the inhibition was up to 30% 






































































Figure 36. mRNA expression of acidic mammalian chitinase, gob-5 and other 
protein targets in lung tissues from mouse asthma model. PCR products were 
separated in a 2% agarose gel and visualized under UV light. The 
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Figure 37. Chitinase bioactivity analysis in BAL fluid. Chitinase bioactivity was 
expressed as concentration (μM) of fluorescent product 4-methylumbelliferone 
generated during the process of the assay. SS (saline/saline, n=4), OS 
(OVA/saline, n=4), OO (OVA/OVA, n=9), D1 (dexamethasone 1 mg/kg, n=8), 
D5 (dexamethasone 5mg/kg, n=8). *Significant difference from OVA/OVA 
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5.2. Discussion  
Glucocorticoid is the most effective anti-inflammatory agent for asthma. In 
biopsy samples from patients with asthma, pro-inflammatory transcription 
factors such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1) are 
markedly activated (Barnes and Adcock, 1998; 2003), and the activity of 
histone acetyltransferase (HAT) responsible for opening up chromatin favoring 
gene expression is increased while the activity of histone deacetylase (HDAC) 
responsible for closing up chromatin leading to gene repression is decreased 
(Barnes and Adcock, 2003; Barnes et al., 2005). As a result, allergic airway 
inflammation is characterized by increased pulmonary expression of pro-
inflammatory cytokines, chemokines, adhesion molecules and other 
mediators (Barnes and Adcock, 2003). It is now believed that the primary 
molecular anti-inflammatory mechanism of action of glucocorticoid is by 
activating glucocorticoid receptors, leading to translocation of the 
glucocorticoid receptors into the nucleus, and through protein interaction with 
coactivators downstream of NF-κB and AP-1, inhibition of HAT activity and 
stimulation of HDAC activity (Barnes and Adcock, 2003; Barnes et al., 2005). 
Glucocorticoid is able to inhibit the expression of a wide array of inflammatory 
mediators; however, the full spectrum of protein targets of glucocorticoid is not 
understood. The present study utilized proteomics technology to explore 
global differential protein expression in mouse BAL fluid in response to 
intratracheally given dexamethasone. We have identified for the first time two 
new protein targets, among many others, acidic mammalian chitinase and 
gob-5, which can be regulated by dexamethasone and may be considered as 
therapeutic targets and/or biomarkers for asthma.  
 150
Chitinases belong to the family 18 of glycosyl hydrolases that can cleave β-
glycosidic linkages between N-acetylglucosamine residues of chitin molecules 
(Donnelly and Barnes, 2004; Owhasi et al., 2000). Chitin is not expressed in 
mammals but is found abundantly in parasitic nematodes, crustaceans, 
insects and fungi (Baak et al., 2005). Notwithstanding, at least seven 
chitinases are found to be expressed in mammals, which include 
chitotriosidase, AMCase, human cartilage glycoprotein-39 (HC-gp39), porcine 
gp38K, mouse brp39, and mouse Ym1 and Ym2 (Nio et al., 2004). Human 
chitotriosidase, AMCase and HC-gp39 have been linked to various 
inflammatory diseases, but only chitotriosidase and AMCase possess 
chitinolytic activity (Boot et al., 2001). Chitotriosidase has been shown to be a 
biomarker for Gaucher disease (Vellodi et al., 2005). HC-gp39 has been 
linked to the development of rheumatoid arthritis and osteoarthritis (Johansen 
et al., 2001). We have recently reported a concurrent up-regulation of 
AMCase, Ym1 and Ym2 proteins in BAL fluid from mouse allergic airway 
inflammation using proteomics approach. Others have shown that TH2 
cytokine IL-13 given intratracheally elevated Ym1 and Ym2 levels in BAL fluid 
from mice in vivo (Webb et al., 2001) and IL-4 induced Ym1 expression in 
mouse peritoneal macrophages in vitro (Welch et al., 2002). These findings 
implicate a potential role of AMCase, Ym1 and Ym2 in asthma pathogenesis. 
Indeed, a recent study demonstrated an increase in AMCase level in an IL-13-
dependent manner in a mouse asthma model and in asthmatic subjects, and 
an anti-inflammatory effect in a mouse asthma model by using polyclonal 
antibody targeted at AMCase or chitinase inhibitor allosamidin (Zhu et al., 
2004). Although Ym1 and Ym2 do not contain chitinolytic activity as the two 
 151
conserved acidic residues (Asp and Glu) key to chitinase activity are missing 
in the catalytic domain, they have been shown to specifically bind to 
carbohydrate moieties such as GlcN oligomers and other glycosaminoglycans 
such as heparin and heparan sulfate to regulate eosinophil chemotaxis, 
inflammation and tissue remodeling (Owhasi et al., 2000; Chang et al., 2001).  
In this study, we observed that dexamethasone significantly blocked the 
expression of AMCase, Ym1, and Ym2 proteins, but not chitotriosidase, in 
BAL fluid and mRNA in lung tissues, and partially inhibited the chitinase 
bioactivity in BAL fluid from OVA/OVA mice. The modest inhibitory effect of 
dexamethasone on chitinase bioactivity in BAL fluid is likely due to the fact 
that dexamethasone suppressed the expression of only AMCase but not 
chitotriosidase, the other chitinase member having chitinolytic activity. As 
AMCase, Ym1 and Ym2 have been implicated in TH2-mediated inflammatory 
responses, the down-regulation of chitinase expression by dexamethasone 
can be considered as a novel anti-inflammatory mechanism of action of 
glucocorticoid in asthma. Cumulative evidence has shown that the expression 
of chitinases (AMCase, Ym1 and Ym2) is controlled by TH2 cytokines such as 
IL-4 and IL-13, and AMCase has been shown to mediate IL-13 effects in 
pulmonary inflammatory cell infiltration and airway hyperresponsiveness (Zhu 
et al., 2004; Webb et al., 2001; Welch et al., 2002). Therefore, it is likely that 
the down-regulation of chitinase level in BAL fluid by dexamethasone is due to 
the inhibition of IL-4 and IL-13 production as shown in the present study and 
by others (Barnes and Adcock, 2003; Eum et al., 2003). In addition to its 
chitinase bioactivity, AMCase may produce airway inflammation by regulating 
cell chemotaxis and airway remodeling via its carbohydrate-binding capability 
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resembling its family members Ym1 and Ym2 (Vellodi et al., 2005; Chang et 
al., 2001).  
Gob-5 (alias mCLCA3), a member of the chloride channel, calcium 
activated (CLCA) family, has previously been shown to play a critical role in 
active export of chloride ions that leads to mucin secretion from airway 
epithelial cells such as goblet cells. The levels of gob-5 and its human 
counterpart hCLCA1 were undetectable in normal airway, but were strikingly 
increased in allergic airway (Nakanishi et al., 2001; Hoshino et al., 2002; 
Gruber et al., 1998). Expression of gob-5 or hCLCA1 in allergic airway has 
been associated with significant induction of MUC5AC, a gene responsible for 
goblet cell metaplasia and mucin production (Nakanishi et al., 2001; Hoshino 
et al., 2002). Depletion of gob-5 protein using antisense oligonucleotide not 
only suppressed mucus production, but also inflammatory cell infiltration and 
airway hyperresponsiveness in asthmatic mice (Nakanishi et al., 2001). The 
present study reveals that the elevation of gob-5 level in allergic airway 
inflammation was detected not only in lung tissues but also in BAL fluid. In 
contradiction, a recent study showed that gob-5 is a secreted non-integral 
membrane protein and therefore is not an ion channel (Gibson et al., 2005), 
and another report using gob-5 knockout mice revealed that gob-5 is not 
essential for mucus overproduction in a mouse asthma model (Robichaud et 
al., 2005). The discrepancies on the role of gob-5 in asthma from these 
reports remain to be resolved. It is now speculated that gob-5, instead of 
being a chloride channel per se, may play a role as a co-initiator or potentiator 
in regulating chloride channel activity for mucus production (Gibson et al., 
2005; Robichaud et al., 2005). The present study clearly showed the dose-
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dependent inhibitory effect of dexamethasone on gob-5 expression in BAL 
fluid and in lung tissues, on MUC5AC mRNA expression in lung tissues, and 
on mucus hypersecretion in allergic airway inflammation. The down-regulation 
of gob-5 and MUC5AC expression by dexamethasone may be considered as 
a novel anti-inflammatory mechanism of action of glucocorticoid in asthma. In 
addition, gob-5 can be used as a biomarker in BAL fluid or induced sputum in 
monitoring glucocorticoid therapy in asthma. 
Aside from chitinases and gob-5, dexamethasone markedly altered BAL 
fluid levels of many other proteins as summarized in Table 2. The significance 
of pharmacological regulation of these proteins in asthma by dexamethasone 
remains to be established. SP-D is a member of the collagenous calcium-
dependent lectin (collectin) family and is mainly synthesized and secreted by 
airway epithelial cells (Haczku et al., 2004). In a mouse asthma model, SP-D 
has been shown to lower blood eosinophilia, pulmonary inflammatory cell 
infiltration, allergen-specific IgE level and TH2 cytokine levels (Madan et al., 
2001). SP-D appears to have an anti-inflammatory role in TH2-mediated 
immune responses (Takahashi et al., 2006). In line with previous report 
(Koopmans et al., 2004), our present study shows an enhanced BAL fluid 
level of SP-D in allergic airway inflammation. Unexpectedly, dexamethasone 
dose-dependently blocked the elevation of SP-D level in the mouse asthma 
model. This is in contrast with the findings that dexamethasone can increase 
SP-D expression in human fetal lung by a direct transcriptional up-regulation 
of the gene (Rust et al., 1996; Dulkerian et al., 1996). However, it has also 
been shown that TH2 cytokines IL-4 and IL-13 are potent stimulators of SP-D 
production from airway epithelial cells (Homer et al., 2002; Cao et al., 2004), 
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and the increase of SP-D level in asthma mice was in a IL-4/IL-13-dependent 
way (Haczku et al., 2006). Therefore, the mechanism by which 
dexamethasone down-regulates SP-D in asthma is likely due to the overall 
repression of TH2 cytokine production (2) including IL-4 and IL-13 as shown 
in the present study. As such, SP-D can be a valuable biomarker not only for 
asthma disease progression but also for monitoring the glucocorticoid effects 
in asthma. 
Lungkine is a member of the ELR-CXC chemokine family characterized by 
a tripeptide motif glutamic acid-leucine-arginine (ELR) immediately preceding 
the CXC sequence (Rossi et al., 1999). It has been shown to distribute 
exclusively in mouse lung, especially bronchoepithelial cells, and regulate 
neutrophil migration in the mouse airways (Chen et al., 2001). In the present 
study, BAL fluid lungkine level was up-regulated in OVA/OVA mice and this 
increased lungkine level was dramatically abated by dexamethasone in a 
dose-dependent manner in 2-DE and immunoblotting/RT-PCR analyses. 
Nevertheless, human homologue of lungkine has not been identified and, 
therefore, its role in human asthma remains to be established. On the other 
hand, dexamethasone down-regulated the elevated BAL fluid levels of 
polymeric immunoglobulin receptor (pIgR), PSTPIP and γ-actin in allergic 
airway inflammation in a dose-dependent manner. PIgR plays a critical role in 
binding of and transcytosis of polymeric IgA and IgM from basolateral surface 
of epithelial cells to the apical lumen, essential for mucosal immunity 
(Phalipon and Corthesy, 2003). TH2 cytokine such as IL-4 has been shown to 
stimulate pIgR expression in epithelial cells (Ackermann et al., 1999). 
Suppression of pIgR BAL fluid level by dexamethasone in allergic asthma may 
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be due to the inhibition of IL-4 level. This is the first observation that 
glucocorticoid can down-regulate pIgR expression in asthma and it may be 
considered as a novel mechanism of glucocorticoid-mediated immune 
suppression. PSTPIP (Cote et al., 2002) and γ-actin (Khaitlina, 2001) are both 
intracellular proteins and their role in allergic airway inflammation is unknown. 
PSTPIP (proline-serine-threonine phosphatase interacting protein) is a 
scaffolding protein that has been shown to bind PTP-PEST (PEST domain-
enrich protein tyrosine phosphatase) and WASp (Wiskott-Aldrich syndrome 
protein). A major biological function of this protein complex is to regulate actin 
rearrangement which has been found to be critical in T cell activation and 
fibroblast migration and cytokinesis (Badour et al., 2004; Angers-Loustau et 
al., 1999). The present study reveals for the first time that dexamethasone 
could inhibit the up-regulation of PSTPIP BAL fluid level in airway 
inflammation. The significance of this inhibitory effect by glucocorticoid in 
asthma remains to be determined. BAL fluid level of hemopexin was not 
altered in allergic airway inflammation but was significantly abated by 
dexamethasone treatment. Hemopexin is a hemoglobin-binding protein and 
has antioxidant activity to protect cells against heme-mediated tissue damage 
(Tolosano and Altruda, 2002). This observation implies that dexamethasone 
may have a weakening effect on the allergic airways to resist oxidative stress. 
Several BAL fluid proteins were found to be down-regulated in our mouse 
asthma model but the down-regulation was halted by dexamethasone 
treatment. These include vitamin D-binding protein (DBP), haptoglobin and α-
1-antitrypsin. DBP is primarily a serum protein but is also present in the fluid 
that lines alveolar epithelium. DBP is an actin scavenger that effectively 
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reduces excessive actin polymerization and its ensuing coagulopathy in 
response to tissue injury. It also enhances C5a-induced neutrophil chemotaxis 
and mediates macrophage activation and subsequent apoptosis (Gomme and 
Bertolini, 2004). Haptoglobin is another hemoglobin-binding protein mainly 
produced by the liver but the lung has been identified as a major extrahepatic 
source of this protein. Cumulative evidence has pointed out that haptoglobin 
has immunomodulatory effects in inflammatory lung diseases including 
allergic asthma (Yang et al., 2000). α-1-Antitrypsin is a serine proteinase 
inhibitor which plays a critical role in inhibiting neutrophil elastase in the 
airways, and its deficiency can lead to severe pulmonary emphysema (Eden 
et al., 1997), and development of airway hyperresponsiveness and reduction 
of lung function (von Ehrenstein et al., 2004). In addition, Vignola and 
coworkers (Vignola et al., 20031) suggested that elastase/α-1-antitrypsin 
imbalance may be important in the development of airway remodelling. Up-
regulation of these protective proteins in the inflamed airways by 
dexamethasone implies potential novel anti-inflammatory mechanisms of 
action of glucocorticoid in asthma therapy. 
During the course of this study, there was a report published on the 
pharmacoproteomics of dexamethasone in allergic airway inflammation (Roh 
et al., 2004). However, in that study, lung tissues instead of BAL fluids were 
used for proteomics analysis, and the protein profiling changes were 
completely different from those reported in the present study. The 
discrepancies observed between these two studies may be due to slightly 
different sensitization and challenge protocols, different genders of BALB/c 
mice, different running condition, and different kinds and sizes of samples 
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(lung tissue, n=4 vs. BAL fluid, n=9). More importantly, an acute mouse model 
was used in Roh’s study but lung tissue was used as the protein source. As 
we mentioned in the introduction, the major limitation of acute asthma model 
is lack of airway structural alterations. That may be the reason that most 
identified proteins only have minor changes in expression levels. 
Nevertheless, they were still able to identify some proteins which were also 
identified in our chronic asthma model study including keratin 7, vesicle amine 
transport protein 1, annexin A3, apolipoprotein A-I and superoxide dismutase. 
That may indicate the potential roles of these proteins in the development of 
chronic asthma.   
In conclusion, dexamethasone elicited complex pharmacological effects on 
protein expression in allergic airway inflammation with some pro-inflammatory 
mediators down-regulated and some protective mediators up-regulated. At 
least 2 critical pathogenic molecules, namely AMCase and gob-5, have been 
identified for the first time to be down-regulated by dexamethasone in allergic 
airway inflammation. They may be considered as novel therapeutic targets for 
































Proteomics has attracted more and more attention from researchers due to its 
unparalleled advantages in large-scale protein profiling. However, only limited 
information can be obtained using proteomics approach in studying human 
asthma, partially because of restricted availability of samples from asthmatic 
patients compared with cancer sample (Houtman and van den Worm, 2005). 
This study is to investigate both BAL fluid and lung proteome alterations in 
either acute or chronic allergic airway inflammation in animal models for the 
first time.         
  A few proteins were identified which have significant up- or down-regulation 
including 24 proteins in BAL fluid from acute asthmatic mice, 13 proteins in 
BAL fluid from chronic asthmatic mice, and 53 proteins in lung tissue from 
chronic asthmatic mice. This comprehensive finding not only reflects the 
complex pathophysiology of asthma, but also provides new insights for 
uncovering novel molecules which can be potential therapeutic targets or 
biomarkers fro asthma. One example is chitinase family proteins. When 
AMCase was identified in this project, there was no report to show the 
relationship between asthma and chitinase proteins. Just a couple of years 
later, people seem to have accepted that the up-regulation of some chitinase 
proteins could be an important characteristic of allergic asthma although the 
functions of these proteins remain unclear. These proteins may open a new 
window to better understanding of asthma.   
  Moreover, we also observed that about 26 proteins in BAL fluid were 
regulated by dexamethasone. Although some changes could be predicted or 
expected, some other changes are interesting and surprising. These proteins 
could be related to the anti-inflammatory effect of dexamethasone, or steroid-
 160
resistance phenomenon.  
  These findings from animal models prompt further studies in human in order 
to validate and testify the correlation of these proteins such as gob-5 with the 
development of asthma. A parallel project has been ongoing during last 2 
years in which samples obtained from humans were used for proteomic 
analysis. Unfortunately, it is quiet unlikely for us to get human BAL fluid and 
lung biopsy in Singapore for many reasons. Alternatively we have collected 
some serum and nasal lavage samples from patients with allergic rhinitis or 
asthma. Due to the highly varied sample quality based on individual 
conditions, e.g. the disease stages and administration of steroids, and limited 
sample number, we have not got unambiguous conclusions so far. One way to 
overcome this problem is to obtain samples from exogenous sources.  
  In addition to the validation study, we are very interested in characterizing 
and exploring the physiological functions of the identified proteins in the 
scenario of asthma. Currently, Ym proteins, AMCase and Fizz1 are our 
primary targets mainly due to the dramatic alterations of their expression 
levels observed in our previous studies and largely unknown biological 
functions. However, that does not exclude the potential significances of other 
proteins in asthma. Some cooperative projects have been set up in our 
laboratory including raising monoclonal antibody, expressing proteins in E.coli 
or mammalian cells system, and functional studies of these proteins in cell 
culture and in our established mouse asthma models. Indeed, we have had 
some interesting findings recently regarding the regulation of AMCase 
expression and cellular distribution of AMCase in asthmatic mouse (data not 
shown). The subsequential study is promising and anticipated.    
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  The shortcomings of 2-DE-based approach prevented us from obtaining 
more findings. Some spots with dramatic alterations in expression level shown 
in gels have not been identified by MALDI-TOF MS due to their low 
abundances. Limited pH and mass range which can be resolved in gels also 
restrict the scope of proteins which can be identified. The lack of information 
on the expression levels of pro-inflammatory cytokines (e.g. IL-4, 5 and 13) 
from our proteomic data has been our concern throughout the study. There 
are detection limitations of this 2-DE proteomics technology that are waiting to 
be resolved. 2-DE is unable to identify proteins of low abundance and of low 
molecular weight. The detection limit for silver staining of 2-D gel is about 1-10 
ng (Hirsch et al., 2004; Fehniger et al., 2004); whereas, the levels of BAL fluid 
IL-4, 5 and 13 are in the range of 10-100 pg/ml (Duan et al., 2004). Therefore, 
we are unable to pick up changes of these low-abundant pro-inflammatory 
mediators using our existing proteomics facility. In contrast, in this study we 
were able to identify novel and unexpected protein targets of glucocorticoid 
using proteomics approach. In contrast, in this study we were able to identify a 
novel chemokine, lungkine, and a novel cytokine Fizz1 which may have 
important role in the development of asthma using proteomics approach. 
Nevertheless, even with these limitations, the power of proteomics is 
undeniable. With predictable advances in technology in future, proteomics will 
contribute more and more to the understanding of a complex disease such as 
asthma.  
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